Advances in differential diagnosis and management of growth hormone deficiency in children

Camille Hage[1], Hoong-Wei Gan[2,3], Anastasia Ibba[4], Giuseppa Patti[5,6], Mehul Dattani[2,3], Sandro Loche[4], Mohamad Maghnie[5,6]&Roberto Salvatori[1†]

[1]*Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.*
[2]*Genetics & Genomic Medicine Research and Teaching Department, University College London Great Ormond Street Hospital Institute of Child Health, London, UK.*
[3]*Department of Paediatric Endocrinology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.*
[4]*Pediatric Endocrine Unit, Pediatric Hospital Microcitemico "A. Cao", AO Brotzu, Cagliari, Italy.*
[5]*Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genova, Italy.*
[6]*Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genova, Italy.*

[†]Email: salvator@jhmi.edu.

Abstract:
Growth hormone (GH) deficiency (GHD) in children is defined as impaired production of GH by the pituitary gland that results in growth failure. This disease may be congenital or acquired, and occurs in isolation or in the setting of multiple pituitary hormone deficiency (MPHD). Isolated GHD has an estimated prevalence of 1 patient per 4,000–10,000 livebirths and can be due to multiple causes, some of which are yet to be determined. Establishing the correct diagnosis remains key in children with short stature, as initiating treatment with recombinant human GH can help them attain their genetically determined adult height. During the past 2 decadesour understanding of the benefits of continuing GH throughout the transition period from childhood to adulthood has increased. Improvements in transitional care will help alleviate the consequent physical and psychological problems that can arise from adult GHD, although the consequences of lack of hormone replacement are less severe in adults than in childhood. In this manuscript, we review the differential diagnosis in children with GHD, including details of clinical presentation, neuroimaging, and genetic testing. Furthermore, we highlight advances and issues in management of GHD, including details of transitional care.

[H1] Introduction

The anterior pituitary gland arises from Rathke's pouch by the 4th to 5th week of gestation. At 8 weeks, the growth hormone (GH) producing somatotroph cells become evident, with abundant immunoreactive cytoplasmic GH expression[1] Defects of the transcription factors involved in pituitary cell differentiation, or defects of GH secretion**,** contribute to a heterogeneous group of diseases with different phenotypes, all characterized by impaired growth due to a variable degree of pituitary deficiency. Growth hormone deficiency (GHD) can be congenital (genetic and/or associated with malformation) or acquired (due to tumours, trauma, inflammation, brain infections or radiotherapy) (**Box 1**; **Supplementary Table 1**; **Supplementary Table 2]**), isolated or associated with other pituitary hormone deficiencies (such as multiple pituitary hormone deficiency (MPHD))[2], and transient or permanent. Most patients have isolated GHD (IGHD) that is idiopathic**.**

GH is a 191-amino-acid protein that is synthesized, stored and secreted in a pulsatile manner by somatotroph cells. The synthesis and release of GH are under the control of various hormones, including GH-releasing hormone (GHRH), somatostatin, ghrelin, insulin-like growth factor-1 (IGF1), thyroid hormone, gonadal steroids and glucocorticoids. Concentrations of GH are higher in the fetal, neonatal and pubertal periods than in adulthood, and increase with chronic malnutrition, exercise, trauma and sepsis[1] .In children and adolescents, GH has a role in increasing bone length and density, however, GH is also important throughout life in increasing muscle mass, and regulating lipid and carbohydrate metabolism and body water**.** Of note, GH circulates in a variety of different isoforms and the most abundant 22kDa isoform best reflects pituitary secretion[3]. Approximately 50% of GH circulates bound to GH-binding protein (GHBP). GHBP has the same amino acid sequence as the extracellular component of the GH receptor (GHR) and its serum concentrations are directly related to the expression level of GHRs**.** Several tissues, especially liver, bone, adipose and muscle, express GHRs.

GH action is exerted directly on target tissues or indirectly by inducing transcription of IGFs. The binding of GH **i**nduces a conformation change of constitutively dimerized GHRs by rotation, with the subsequent activation of a phosphorylation cascade involving the JAK–STAT pathway[4]. STAT proteins then migrate to the nucleus and promote the transcription of various genes, such as those encoding IGF1, IGF2, IGF-binding protein 3 (IGFBP3) and acid-labile subunit (ALS).

The main GH effector is IGF1, a 70-aminoacid peptide with the ability to bind insulin receptor; IGF1 is mostly secreted by the liver and circulates bound to specific IGFBPs (IGFBP1–6). The IGF1 and IGFBP3 binary complex binds to the large protein ALS, creating a ternary complex that prolongs the half-life of IGF1 and IGFBP3 in the circulation[4]. Of note, IGFBP3 has many other IGF1 dependent and independent actions, including both inhibition and enhancement of IGF1 actions and cell proliferation, survival and migration[5]. Furthermore, in addition to GH, malnutrition, thyroid hormone, oestrogens, androgens, chronic diseases, inflammation (such as in coeliac disease or inflammatory bowel disease) and anorexia nervosa can all influence IGF-1–IGFBP-3 action[6].

In this Review, we provide a detailed and up-to-date summary of the evaluation and management of children with GHD. We comprehensively review knowledge in differential diagnosis, including clinical presentation, neuroimaging and genetic testing. We also discuss advances in management, adverse effects associated with GH replacement therapy and transitional care from childhood to adulthood.

[H1] Diagnosis

The diagnosis of GHD in children is based on medical history, auxological and biochemical investigation, radiological skeletal maturation assessment and neuroimaging of the pituitary region[7,8]. Genetic analysis is indicated in selected patients.

[H2] Clinical presentation

The clinical presentation varies depending on the age of onset. For example, GHD in newborns can be isolated but often presents as MPHD. Neonates and infants might have non-specific symptoms and signs, such as lethargy and poor weight gain, or more specific life-threatening emergencies[9], including respiratory distress, apnea, cyanosis, poor feeding, hypotonia, prolonged cholestatic jaundice, severe hypoglycemia with or without seizures, and/or neonatal sepsis**.** Eye abnormalities or nystagmus can be present in patients with optic chiasm involvement. Furthermore, microphallus might be present in IGHD or patients with associated gonadotropin deficiency. Other physical findings can clue into the presence of GHD. For instance, microphthalmia and single central maxillary incisor can be associated with hypopituitarism in holoprosencephaly, whereas midface hypoplasia and frontal bossing suggest GHD independently

from its aetiology[10,11] Intrauterine growth is generally not affected by GHD, and birth weight and length are usually within normal limits, although might be slightly reduced.

The typical GHD clinical phenotype in childhood is persistent growth failure and short stature associated with frontal bossing, depressed nasal bridge, immature appearance, mid-facial hypoplasia, delayed dentition, truncal adiposity and micropenis. However, the most common presentation in adolescents is growth retardation and delayed puberty; facial, axillary and pubic hair are usually lacking[12]. Most cases of IGHD in childhood and adolescence are idiopathic; however, brain tumours, infiltrative conditions such as histiocytosis, and infections of the central nervous system should always be considered[13]. Cranial irradiation and brain injuries might cause IGHD or MPHD. Some case reports have described the unexplained phenomenon of normal growth during childhood in the absence of GH[14], particularly in association with craniopharyngioma. Possible explanations include the hyperinsulinaemia and hyperleptinaemia associated with obesity, hyperprolactinaemia, as well GH variants that are not measured by monoclonal assays and could maintain normal serum concentrations of IGF1.

Similarly to IGHD, MPHD is heterogeneous, and can be congenital (genetic, perinatal injuries, malformation, trauma or pituitary stalk dysgenesis) or acquired (tumours and or surgery) (**Box 1**) [13]. The clinical features vary depending on the type of cells affected. In some cases, a specific phenotype can be associated with a particular genetic mutation (for example,*POU1F1* mutations cause GH, TSH and PRL deficiencies). Hormonal deficiencies can become evident at different ages throughout life.

[H2] Auxology

In children with suspected GHD (**Box 2**), an accurate history includes measured parental heights. Physical examination involves measuring the weight, head circumference and standing height, or supine length if <2 years old, via accurate instrumentation. Body proportion, BMI, fontanels, dentition, external genitalia, pubertal status and presence of dysmorphic features should be assessed[7]. Furthermore, height velocity should be determined through serial measurements with a minimum interval of 6 months. Of note, skeletal maturity reflects the child's biological age and provides an important contribution to the diagnostic workup.GHD is unlikely in patients without considerable bone age delay(18–24 months delayed from chronological age)[8].

[H2] Laboratory investigation

[H3] GH thresholds. The clinical suspicion of neonatal GHD can be confirmed by a single GH measurement, preferably obtained during a hypoglycaemic episode, from plasma, serum or newborn blood screening cards[15] within the first week of life. Hypoglycaemia should be confirmed in plasma after rapid sample processing, as the glucose concentration decreases over time. A GH cut-off level that diagnoses GHD in infants has yet to be established[15-17]. Twenty years ago, a random GH measurement<20 μg/L suggested GHD in the newborn[8], whereas in 2020, Binder and colleagues[15] reported that GH <7 μg/L in the term newborn blood screening card confirms severe GHD with high accuracy. Most guidelines[16] suggest a 5 μg/L cut-off in newborns with additional pituitary hormone deficiencies, or with the triad of ectopic posterior pituitary**,** anterior pituitary hypoplasia and abnormal pituitary stalk.The specificity of a single GH measurement during spontaneous hypoglycaemia has been questioned; however, normal GH concentration can be useful to exclude GHD[18]. Simultaneous evaluation of cortisol and thyroid hormone concentrations is also recommended. In the case of confirmed biochemical IGHD or MPHD, brain MRI should be obtained (discussed later).

[H3] GH stimulation testing.In infancy and childhood, in the absence of signs and symptoms indicative of GHD (**Box 2**), other causes of short stature should be ruled out. GH stimulation tests might be required to assess GH secretory capacity. A diagnosis of GHD without GH provocative testing is suggested only in patients that satisfy all the following criteria: auxological characteristics, presence of hypothalamic–pituitary defects on neuroimaging (congenital or acquired) and one additional pituitary hormone deficiency[16].

Many stimulation tests to evaluate GH secretion exist[7,8,19-21]. Clonidine, glucagon, arginine and the insulin tolerance test are the most routinely used. The insulin tolerance test is considered the gold standard and is used to assess GH secretion in response to hypoglycaemia. However, interpretation of the test result is challenging due to an abundance of false-positives, thereby indicating low specificity and poor reproducibility[22,23]. Albeit less frequently, false-negatives are observed[11]. These issues are due to several factors: for example, the stimuli are not physiological and do not replicate normal secretory dynamics and the periodic secretion of somatostatin might

influence the somatotroph response. Additional factors such as obesity, undernutrition, sex, age and puberty also influence GH secretion[3]. For example, GH responses to stimulation tests decrease with increasing BMI[24].

GH secretion increases during puberty and after the administration of sex steroids[25]. In short peripubertal children with delayed puberty, GH testing might yield abnormal results. The most recent guidelines of the Pediatric Endocrine Society published in 2016[16] recommend the use of sex steroid priming before GH testing in prepubertal males>11 years and prepubertal females>10 years. Sex steroid priming enhances GH secretion and reduces the number of false-positive results (26-28). However, when priming is used, GH secretion might be enhanced in a non-physiological manner and can cause false-negative tests, thereby depriving a child of potentially beneficial replacement therapy[26]. Therefore, priming remains controversial[26] with no consensus among European countries[20,21]. Although the age for priming most commonly ranges from 10 to 13 for boys and from 8 to 12 for girls[20], some centres prime children as young as 7 (boys) and 6 (girls).Of note, the sex steroid preparation and dose differ between centres, and only 25–50% of children undergoing GH testing are primed[20,21]. The steroid preparation used is mostly oral 17β-estradiol or stilboestrol[27] for 2–7evenings preceding the test, or 50–100 mg intramuscular testosterone enanthate administered 1 week ahead[16].

Owing to poor accuracy, confirmation of a GHD diagnosis requires two failed tests. The provocative tests should be performed after an overnight fast using a standardized protocol under the supervision of an expert team, preferably on two different days. A peak GH concentration below 7 μg/L has been suggested[16]. However, the diagnostic GH peak cut-off is still a matter of discussion ranging between 5 to 10 μg/L[7,8,20,23,28-30].

Assay discrepancies across different laboratories contribute to the variability in GH test results. This variability can be reduced if a common pure standard preparation is used for calibration[28]. As suggested by guidelines[11,16,28,31], the best assays should measure the 22kDa isoform, as it most accurately reflects pituitary GH secretion. Over the past decades, GH assays have changed considerably from non-specific radioimmunoassays to highly sensitive chemiluminescence immunoassays. Although the older assays recognized a spectrum of different GH isoforms together with their homodimers, heterodimers, and multimers, the new monoclonal antibodies recognize a precise epitope, picking a narrow spectrum of circulating GH molecules.

This advance could partly explain the progressively lower GH concentrations obtained during GH stimulation testing over the last 20 years[3].

[H3] Other important biochemical parameters? The interpretation of GH provocative test results should consider all the above aspects as well as other biochemical parameters such as IGF1 and IGFBP3, which are positively correlated with GH secretion(2). Their serum concentrations show little circadian variation. Because GH is, on the contrary, secreted in a pulsatile fashion, a single IGF1 and IGFBP3 measurement is more reliable than a single GH value. For these reasons both IGF1 and IGFBP3 have been investigated as alternatives to GH stimulation testing[32-35] and proposed as markers of GH treatment[36]. Of note, IGF1 and IGFBP3 concentrations are influenced by the type of assay[37,38], nutritional status, and the presence of chronic illnesses or organ failure, and should be interpreted with regard to age, sex and pubertal status[6,39]. According to some authors, bone age can be used as a surrogate for pubertal status when interpreting IGF1concentrations; this parameter is particularly relevant in the peripubertal age group when the probability of constitutional delay is greater than IGHD[40,41].

Several studies have addressed the accuracy of IGF1 and IGFBP3 in the diagnosis of GHD. Most[20,30,33,36] have shown that IGF1 has a good or moderate specificity but low sensitivity to diagnose GHD, meaning that low IGF1 values at ≤-2.0 Standard Deviation Score (SDS) are highly predictive of GHD, and values >0.0 SDS modified by age, sex and pubertal maturation make GHD highly unlikely[28,42,43]. Serum concentration of IGF1 has been reported to of be particularly poor sensitivity in diagnosing GHD in children who underwent cranial irradiation[44]. In young children, IGFBP3 measurement, which usually offers no advantages over IGF1, might provide additional information as it correlates well with integrated GH secretion and might be more sensitive than IGF1 in the diagnosis of GHD[3,6,19].

Measurement of ALS is not routinely performed since it adds no information to the GH stimulation test, or IGF1 and IGFBP3 measurements. ALS measurement is only indicated when ALS deficiency [(OMIM #615961)] (https://www.omim.org/entry/615961) is suspected[45].

Overall, the decision to perform a GH stimulation test should therefore be based on the severity of short stature, height velocity, history, physical examination, radiological findings and evaluation of IGF1 and IGFBP3 concentrations[16].

[H1] Genetic diagnosis of growth hormone deficiency

A genetic origin should be considered in the presence of parental consanguinity, positive family history, craniofacial or brain midline abnormalities or other syndromic features suggestive of a genetic aetiology[46].Diagnosis of the underlying genetic disorder in congenital GHD is not always straightforward, as current knowledge of the genes implicated in pituitary development remains incomplete, and >80% of patients with MPHD have no genetic diagnosis[2,46]. In addition, determination of pathogenicity of individual genetic mutations in IGHD and/or MPHD can be challenging, as in most patients the disease is probably caused by digenic, oligogenic, epigenetic and/or environmental factors[2]. Next-generation sequencing technologies (whole-exome sequencing and whole-genome sequencing) might enable more rapid analysis of multiple genes compared with the more laborious candidate gene approach using Sanger sequencing. Whole-exome sequencing might be limited by incomplete coverage, and both whole-exome and whole-genome sequencing can bring problems of data overload, which require refined bioinformatic analyses. As such, the candidate gene approach can still prove useful in situations where extra-pituitary features might point to a specific underlying diagnosis.

[H2] Isolated GH deficiency

IGHD is the commonest form of congenital hypopituitarism, with an incidence of 1 in 4,000 to 10,000 live births, of which 3–30% are familial[47,48] . IGHD is inherited in an autosomal recessive (types IA, IB, IV and V), autosomal dominant (type II), or X-linked recessive (type III) manner, usually due to mutations in the genes encoding GH (*GH1*) and the GHRH receptor (*GHRHR*)(**Box 1**, **Supplementary table 1**)[49]. Of note, IGHD can also arise due to dominant or recessive mutations in developmental transcription factors that influence somatotroph development as part of the normal development of the anterior pituitary (*HESX1*, *SOX3*, *OTX2*, *PROP1* or*POU1F1*)[49]. In this latter scenario, GHD is often the initial presentation before the evolution of subsequent multiple pituitary hormone deficiencies, although GHD mightremainas the only endocrinopathy.

[H3] GH1 mutations.The *GH1* gene (17q22-24) consists of five exons and is translated into three protein products by alternative splicing, with molecular weights of 22 kDa (191 amino

acids, 75% abundance relative to other isoforms), 20 kDa (176 amino acids, 5–10%), and 17.5 kDa (151 amino acids, 1–5%)[49,50]. The 20 kDa and 22 kDa isoforms are biologically active. The severity of IGHD correlates with the deleteriousness of a given mutation. For example, homozygous *GH1* deletions result in type IA IGHD and early, severe growth failure (height <-4.5 SDS, undetectable GH concentrations and tachyphylaxis to GH treatment due to the formation of anti-GH antibodies in most, but not all, patients[51-53]. Type IA IGHD can also result from severe truncation of the GH molecule secondary to other homozygous or compound heterozygous mutations [45,54,55]. By contrast, patients with type IB IGHD have low but detectable GH concentrations and a persistent response to treatment[49].

The commonest form of genetic IGHD, type II IGHD , is also the most variable in terms of age at presentation and degree of growth failure, with some carriers achieving a height within the normal range[55,56]. This form is caused by splice site or missense mutations in *GH1* that result in low, detectable GH concentrations and occasional anterior pituitary hypoplasia[57,58]. Patients with type II IGHD can develop other pituitary hormone deficits, due to a dominant-negative effect of the 17.5 kDa GH isoform on bioactive 22 kDa isoform production[59,60]. This effect results in protein misfolding and ultimately in impairment of secretory pathways for other pituitary hormones (adrenocorticotropic hormone (ACTH), TSH or luteinizing hormone (LH)). Type II IGHD can also arise from the generation of bioinactive GH, which either fails to activate the GH receptor or results in reduced downstream gene transcription[61,62].

[H3] GHRHR mutations. Homozygous or compound heterozygous *GHRHR* mutations cause type IV IGHD, classically presenting with severe growth failure, extremely low GH concentrations that are poorly responsive to stimulation, low concentrations of IGF1 and IGFBP3, and good response to GH replacement therapy[63,64] . Midfacial hypoplasia, neonatal hypoglycaemia, and microphallus are less common than in type IA IGHD, although anterior pituitary hypoplasia is very common due to the trophic effect of GHRH on somatotroph proliferation[49,65]. Compound homozygous *GHRHR* mutations (such asc.11G>A andc.236C>T, [p.Arg4Gln and p.Pro79Leu respectively]) have additionally been described in association with a mild phenotype (untreated near-adult female height of 144 cm, –3.0 SDS) or presentation in mid-childhood (6–8.5 years)[66].

[H3] Other molecular mechanisms associated with IGHD. The GH secretagogue receptor (GHSR) regulates GH release via its endogenous ligand, ghrelin[67]. Both autosomal dominant and recessive mutations in this receptor have been reported, resulting in a phenotype that ranges from normal GH secretion to partial IGHD, possibly due to a loss in constitutive receptor activity[68,69].

Recessive mutations in*RNPC3*, which encodes a specific protein component of the minor spliceosome**,** have also been described in association with IGHD type V. The phenotype includes severe postnatal growth retardation, undetectable GH concentrations even on stimulation, undetectable IGF1 and IGFBP3, low–normal prolactin concentrations and anterior pituitary hypoplasia[70]. A 2020 study described the presence of compound heterozygosity for two variants in *RNPC3*, namely c.443G>C, p.[Gly148Ala], and c.259C>T, p.[Gln87*], in three siblings from an Afro-Caribbean family[71]. The phenotype included the presence of other pituitary hormone deficiencies: TSH and prolactin deficiency with hypogonadism, although no gonadotrophin data were presented.

[H2] Multiple pituitary hormone deficiency

MPHD is defined as the presence of two or more pituitary hormone deficits and can be syndromic or non-syndromic (**Box 1** , **Supplementary table 2**).MPHD's presentation can occur in the neonatal period or later in life. Syndromic MPHD refers to the association of pituitary hormone deficiencies with abnormalities in other structures that share a common embryological origin such as the eyes, midline structures or forebrain. The number of syndromic MPHD-associated genes continues to increase; however, in most patients a genetic defect still cannot be identified.

[H3] Non-syndromic MPHD. Some studies have reported that up to 50% of familial MPHD is caused by recessive mutations in *PROP1*; the most common mutation is a deletion in exon 2 that leads to protein truncation[72,73]. *PROP1* expression triggers downstream expression of *POU1F1*, which induces terminal differentiation of somatrotrophs, thyrotrophs and lactotrophs. In addition, *PROP1* expression determines the cell lineages that secrete LH and FSH[74]. As such mutations in *PROP1*are associated with GH, TSH, PRL, LH and FSH deficiencies, however, patients with such mutations also show a generally late onset of ACTH deficiency but the underlying mechanism is unclear. Of note, the timing of hormonal deficiencies can vary even in patients

carrying identical mutations, and importantly, deficiencies can evolve over time. Mutations in *PROP1*can also cause apparent pituitary masses that wax and wane over time, ultimately leading to anterior pituitary involution[75,76].

The second most common form of familial MPHD (25%) is caused by mutations in *POU1F1*,which are associated with GH, TSH and PRL deficiencies[77]. Most mutations are recessive; however, a frequently occurring heterozygous mutation (p.R271W) has also been identified, where the protein product acts in a dominant-negative manner and inhibits transcriptional activity of the wild-type protein[77,78]. Patients with *POU1F1* mutations have been reported to date in a predominantly expressed alpha isoform. A recent study has described mutations in a minor alternatively spliced beta isoform of POU1F1 that are associated with IGHD, with TSH deficiency that can be early or develop much later[79,80].

Mutations in genes such as *ROBO1*, *FOXA2*, *CDON* and *GPR161* have been associated with pituitary stalk interruption syndrome([PSIS] [https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=95496], discussed later) and MPHD. Mutations in *CDON* are associated with non-syndromic MPHD[81], whereas *ROBO1*, *FOXA2*, and *GPR161* mutations are associated with other extra-pituitary clinical features[82-84].

[H3] Syndromic MPHD. One form of syndromic MPHD is septo-optic dysplasia (SOD), which is defined by the presence of at least two of the triad of optic nerve hypoplasia, midline forebrain defects and pituitary hypoplasia, or hypopituitarism[85]. Of these, 30% of patients have all three features and 62% have hypopituitarism[86]. Neuroradiological abnormalities can include anterior pituitary hypoplasia, or an ectopic posterior pituitary or an absent infundibulum, all predictors of hypopituitarism[87]. Mutations in genes encoding transcription factors involved in early pituitary development such as *HESX1* (homozygous and heterozygous) and *TCF7L1* (heterozygous) have been found in some patients with SOD[88,89]. However, its aetiology remains multifactorial, with other environmental factors (such as viral infections, vascular changes, alcohol or drug exposure) being possibly implicated, with incidence being higher in children born to younger mothers than older mothers[90]. Of note, a 2020 study suggested considerable differences between patients with SOD and patients with MPHD without associated midline abnormalities, in terms of the timing and nature of endocrinopathies, and the likelihood of spontaneous puberty[91].

The co-existence of MPHD with ocular abnormalities, such as anophthalmia or bilateral microphthalmia, suggests the presence of genetic mutations in either *SOX2*, *OTX2* or *RAX*. In *SOX2* or *OTX2*, only autosomal dominant mutations have been described. The classic presentation of *SOX2* loss-of-function mutations is hypogonadotrophic hypogonadism and variable GH deficiency; however, these mutations can also be associated with other abnormalities including spastic diplegia, epilepsy, esophageal atresia and/or tracheoesophageal fistula, hypothalamic hamartoma, hippocampal hypoplasia, ventriculomegaly, absent septum pellucidum, corpus callosum agenesis, sensorineural hearing loss and male genital tract abnormalities[92-94]. By contrast, patients with *OTX2*mutations can present with IGHD or MPHD, but these mutations might also be associated with retinal degeneration, ectopic posterior pituitary or even completely normal eye development[95-96]. In 2019, compound heterozygous and homozygous mutations in *RAX* were reported in association with anophthalmia, MPHD with central diabetes insipidus, and cleft lip and palate[97].

X-linked mutations in *SOX3* have been reported in association with type III IGHD or MPHD and anterior pituitary hypoplasia. Other more variable features of these mutations include mental retardation or developmental delay, posterior pituitary ectopy, or the presence of a persistent craniopharyngeal canal[98-100]. Of note, mutations in *OTX2* and *SOX2* can also be associated with developmental delay.

Mutations in the LIM family of homeobox genes *LHX3* (homozygous and compound heterozygous) and *LHX4* (homozygous and heterozygous) have been reported in MPHD. Mutations in these genes can be associated with a normal, hypoplastic or even enlarged pituitary gland[101]. *LHX3* mutations are linked with a short neck with limited rotation, spinal abnormalities and sensorineural hearing loss[102,103]. By contrast, in *LHX4* mutations, the neck and hearing are normal, but other features can include an ectopic posterior pituitary, hypoplastic corpus callosum and Chiari malformation[101]. Homozygous *LHX4* mutations are associated with early neonatal death and severe panhypopituitarism[104]). In 2015, homozygous loss-of-function mutations in *PNPLA6*(the causal gene responsible for Oliver-McFarlane and Laurence-Moon syndromes)were associated with progressive cerebellar ataxia or atrophy, chorioretinal dystrophy, and variable hypopituitarism that ranged from GH and TSH deficiencies to normosmic hypogonadotrophic hypogonadism[105].

Of note, in holoprosencephaly**[G]**, central diabetes insipidus is the most common form of hypopituitarism. However, holoprosencephaly with MPHD or panhypopituitarism has been associated with mutations in *GLI2*, *FGF8* and *TGIF1*[106-108]. The list of genetic syndromes associated with GH deficiency is rapidly expanding and includes mutations in *BMP4*, *PITX2*,*ARNT2*, *EIF2S3, FOXA2*,the ciliopathy gene *IFT172*, the channelopathy gene *KCNQ1*, *ROBO1*, *GPR161*,*TBC1D32*, and *GLI3*[2,109]. Many of these genes (*BMP4*, *GPR161*, *EIF2S3*, *IFT172* and*KCNQ1*) are also implicated in early hypothalamo–pituitary development[2,109]. Several genes associated with Kallmann syndrome (*ANOS1*, *FGFR1*, *PROKR2*, *CHD7* and*WDR11*) have also been described in association with GH deficiency, MPHD and SOD[2,110,111]. Finally, mutations in genes more predominantly associated with other forms of hypopituitarism such as *IGSF1* (central hypothyroidism) and *PCSK1* (ACTH deficiency) can also be associated with GH deficiency and MPHD[112,113].

[H3] Pituitary stalk interruption syndrome. PSIS is a rare spectrum of congenital abnormalities of the pituitary gland with an absent or ectopic posterior pituitary thin, hypoplastic or interrupted pituitary stalk, with or without hypoplasia or aplasia of the anterior pituitary gland[108,114-120]. The syndrome is more common in boys, has a variable age at diagnosis and also occurs sporadically in the majority of patients[114,115-119]. Recombinant GH post-marketing surveillance databases suggest that around 4–8% of patients with GHD have PSIS[117-120].

Only 5% of patients with PSIS have identifiable genetic mutations, and several genes that overlap with other causes of GHD and MPHD (for example, *CDON*, *HESX1*, *OTX2*, over-dosage and under-dosage of *SOX3*, *LHX4*, *GLI2*, *TGIF1*, *FOXA2*, *IFT172*, *ROBO1*, *GPR161* and *TBC1D32*) have been associated with ectopic posterior pituitary. An association also exists between PSIS and other midline defects[102,115,116,118,121]. Digenic inheritance (for example,*PROKR2* and *WDR11*[122]) has also been reported. Furthermore an association can occur between PSIS and extrapituitary abnormalities such as biliary ciliopathy with homozygous *TTC26* mutations[123] and Fanconi anaemia[119,124,125].However, like SOD, a polygenic and multifactorial aetiology is probable, and, in one study, up to 83% of patients with sporadic PSIS have multiple heterozygous variations in genes largely affecting Notch, Shh and Wnt signalling[124]. More recent whole-exome studies from 2018 and 2020 have identified further

candidate genes (for example, *FAT2, DCHS1, DCHS2, ROBO2, CCDC88C, KIF14*and *KAT6A*)[126,127].

[H1] Neuroimaging in Hypopituitarism

The diagnostic accuracy of MRI has led to an enormous increase in our knowledge of pituitary morphology and function, which has improved the differential diagnosis of hypopituitarism[114,119]. MRI hasalso improved the early identification of neuroimaging hallmarks of evolving anterior pituitary hormone deficiencies, the prediction of long-term outcomes, and aided genetic counselling A brain MRI should be performed in children with GHD to avoid missing hypothalamic–pituitary abnormalities or tumours[85]. Equally, MRI of the hypothalamic–pituitary region in neonates or infants with hypoglycaemia and symptoms that suggest congenital hypopituitarism, during the neonatal and postnatal period, is valuable in identifying midline defects and pituitary abnormalities[7].

[H2] MRI Protocol in Hypopituitarism

The correct interpretation of MRI scans requires detailed knowledge of the normal features of the pituitary gland and of its changes within the same individual over time (**Supplementary Table 3**)[128,129]. The assessment includes the evaluation of signal intensity, shape, size, position of the anterior pituitary, posterior pituitary and pituitary stalk, and connection with surrounding tissues (**Figure 1**). In addition to high-resolution sellar MRI, one or more survey sequences of the entire brain, a fluid attenuation inversion recovery and a diffusion-weighted-imaging sequence on the axial plane should be acquired to rule out additional CNS abnormalities; post-contrast imaging can safely be omitted in patients with IGHD, ifT2-DRIVE**[G]**(**Figure 1D**) has been performed[130].

[H2] MRI Findings in Hypopituitarism

Patients with idiopathic, congenital, or genetically-determined GHD can present with one of three different phenotypes. First, with normal or hypoplastic pituitary gland or empty sella, normal or thin pituitary stalk, and normal hypothalamic–pituitary connection with or without CNS abnormalities. Second, with anterior pituitary hyperplasia or intermittent hyperplasia or enlarged sella. Third, with moderate to severe hypoplastic pituitary gland or small sella, thin or

hypoplastic or absent pituitary stalk with an ectopic posterior pituitary (sometimes double)that is located anywhere from the median eminence to the distal stalk (as seen in PSIS)[114,115,119]. IGHD is more commonly associated with either normal pituitary anatomy or hypoplastic anterior pituitary or empty sella with normal pituitary stalk, whereas PSIS is most frequently associated with MPHD. Rarely, the anterior pituitary could be hyperplastic with normal posterior pituitary location and normal pituitary stalk[114,115,119], whereas congenital absence or agenesis or atrophy of the pituitary gland is very uncommon[9,116] (**Table 1**)

[H3] Hypopituitarism with normal pituitary stalk. Pituitary hypoplasia is defined as a small anterior pituitary housed within a small or normal pituitary fossa, and can either be isolated or might occur as a part of complex malformative syndromes including SOD and/or forebrain, midbrain and hindbrain abnormalities[131]. Previous studies in children with hypopituitarism have reported a prevalence of normal pituitary of 1–44%or anterior pituitary hypoplasia of 19–84%[119]. These findings vary among reports, however, two large studies in more than 13,000 and 8,000 children, showed that 80–86% have normal pituitary gland anatomy whereas 4–9% have hypoplasia[117,120].

The inappropriate use of anterior pituitary hypoplasia as a synonym for partial or total empty sella is worth mentioning. In essence, empty sella (also called intra-sellar arachnoidocele) indicates an intrasellar herniation of the subarachnoid spaces through an incompetent sellar diaphragm (arachnoid diverticulum), where the pituitary gland narrows or flattens with consequent enlargement of the pituitary fossa[132]. In addition, the posterior lobe is flattened against the dorsum sellae and the pituitary stalk appears thin and elongated. Secondary empty sella can develop after surgery, radiotherapy or vascular atrophy. In such cases, it is essentially an “ex vacuo” phenomenon where intracranial subarachnoid space secondarily extends into the sella. Empty sella is seldom causally associated with hypopituitarism with a prevalence in children with hypopituitarism between 5–9% that increases with age[132]. An empty sella is reported in about 10% of patients with IGHD[133], and the presence of a small pituitary fossa might help to distinguish pituitary hypoplasia from a partially empty sella. MRI findings in patients with genetic forms of IGHD or MPHD are summarized in **Table 1**[75,76,109,114,116,119,134,135].

[H3] Hypopituitarism with pituitary stalk interruption syndrome. PSIS is characterized by its classic triad as mentioned earlier. However, in the last decades, PSIS has been widened to include patients with one feature such as ectopic posterior pituitary, or interrupted stalk, or interrupted pituitary stalk with absent posterior pituitary[115,118]. Rarely, double or partial ectopic posterior pituitary could be documented[114-116,119,136] (**Figure 2**). PSIS remains a complex etiology involving several factors (epigenetics, environment, drugs and genetics).

Animal experiments show that pituitary stalk transection results in the formation of an ectopic posterior pituitary, and that pituitary stalk ischaemia resulting from perinatal asphyxia or breech delivery is associated with ectopic posterior pituitary[137-140]. These findings suggest that PSIS arises as the result of a triggering perinatal event that causes hypoxia on the background of a genetic predisposition. This congenital hypothesis is supported by Maghnie et al.[140] and subsequently by Pinto et al. in a large series of PSIS suggesting a prenatal origin[141].

By contrast, perinatal injury has been reported in >80% of patients with hypopituitarism[139,140]. For instance, the increased prevalence of maternal antenatal drug and alcohol abuse, as well as a lower maternal age inchildren with SOD, led Lubinsky[142] to suggest that SOD mightoccur secondary to a prenatal vascular disruption sequence. Yet, a lack of experimental evidence supports the vascular origin. Therefore, the role of prenatal environment or birth trauma remains possible and the worsening of a pre-existing condition due to hypoxia could not be disregarded. Additionally, pituitary abnormalities mighthave a role in increasing the risk of breech presentation, based on data showing that breech delivery is five times more common in patients with hypothalamic–pituitary abnormalities associated with MPHD[143,144].

Indeed, after the congenital hypothesis was proposed, subsequent MRI findings of ectopic posterior pituitary in several patients with GHD carrying genetic mutations[109,115,116,121,145] were largely favourable to a prenatal origin hypothesis. In these studies, the prenatal hypothesis was evidenced by the association of GHD with several midline defects, the absence of perinatal adverse events in two-thirds of patients, with cephalic delivery for about 50% and caesarean section for 15% of patients, as well as the association with familial cases and mutations in several genes encoding transcription factors involved in embryonic hypothalamic–pituitary developmental processes.

[H3] Hypothalamic–pituitary MRI anatomy and pituitary function. Several studies have reported increased rates of ectopic posterior pituitary in patients with MPHD than in patients with IGHD[114,119,140,143,144,146]. MRI identification of the triad of ectopic posterior pituitary, anterior pituitary hypoplasia and pituitary stalk agenesis is of great value in recognizing patients at risk for evolving pituitary hormone deficiencies. In particular, small size and location of ectopic posterior pituitary are predictive of MPHD development[146,147].

By contrast, the presence of a vascular component of the stalk has a positive prognostic value, as patients in whom a pituitary stalk cannot be identified after administration of the contrast agent gadolinium-DTPA have a 27 times greater risk of developing MPHD than those with a residual vascular pituitary stalk[148]. A detailed study of the pituitary stalk with gadolinium-DTPA is no longer recommended in congenital hypopituitarism provided T2-DRIVE has been performed[130]. The pituitary stalk can be better recognized by T2-DRIVE than by conventional T1 and T2 weighted images (**Figure 2**). This T2-DRIVE observation raises the question [about its prognostic value in predicting the deterioration of pituitary defects[130].

The current data suggest that MRI scans can help predict the response of an individual patient to therapy. The relationship between pituitary MRI characteristics and growth response after treatment with recombinant human GH (rhGH) has shown that hypothalamic–pituitary structural abnormalities are key parameters in predicting growth response[149]. In addition, patients with GHD with ectopic posterior pituitary perform better in terms of adult height achieved than those with normal or hypoplastic anterior pituitary on MRI[117,120].MRI findings in IGHD and MPHD are summarised in **Figure 3**.

[H1] Management

[H2] Treatment with rhGH

The established treatment for GHD in children is rhGH, also known as Somatropin[150]. This aqueous biosynthetic GH is administered subcutaneously at night to follow the GH secretory pattern during sleep[16]. Most pharmaceutical brands, which share a similar effect, have a multiple-dose pen for easier administration. Several sustained-release GH preparations that are administered weekly have been developed since 2007, in order to ease the burden of use[151]; these formulations substantially vary in molecular weight and ionic charge with some using fusion proteins to affect the target tissues' access to GH[152]. Treatments that require fewer injections

might offer increased acceptance, tolerability and flexibility than daily rhGH [153]. Indeed, the lack of adherence to daily rhGH has been hypothesized as the reason why many children remain below the mid-parental target height despite treatment[154]. No significant differences in effectiveness and adverse events have been identified when sustained-released GH was compared with daily rhGH in a meta-analysis of clinical trials published between 2012 and 2018[155].Therefore, long-acting preparations might represent a promising replacement for daily rhGH,with a few questions still not completely answered, such as the methods of dose adjustment, timing of monitoring of IGF1, safety, efficacy and cost-effectiveness[152].Some safety concerns revolve around the formation of anti-drug antibodies in patients, as well as efficacy limitations in large preparations of GH fusion proteins due to size disparity with key target tissues leading to different metabolic side effects [152]. Hence, post-marketing surveillance will be crucial.

[H3] Optimal dosage. Currently, the recommended daily GH dosage based on weight is 0.16–0.24 mg/kg per week (0.022–0.035 mg/kg per day) with a maximum dose that should not exceed 0.3 mg/kg per week[7,16,19]. The dose might be increased at puberty, although this change is not recommended routinely[16]. The medication is best initiated as soon as the diagnosis is confirmed with the optimal outcome occurring while bone growth plates (epiphyses)are open (generally <15y for females and <17y for males[154]. However, the response varies considerably between individuals according to the diagnostic criteria. Patients with less severe GHD and/or those who start medication at an older age will have a worse response to therapy than younger patients with more severe disease respectively[157-159]. Peak GH concentrations during stimulation testing, age at onset of therapy and height difference from mid-parental target height are the most important predictors of the first-year height velocity. Although one would hope that using a personalized rhGH dose that considers these factors could lead to low variability in medication response, studies have questioned the reliability of predictive factors[161].

The method used for dosage refinement has been the subject of much debate[16,160,161].An approach that is broadly used is to adjust the GH dose based on serum concentrations ofIGF1. Although keeping the IGF1 concentration within the age-adjusted normal range is reasonable, no consensus exists on the optimal target level; some studies have reported increased concentrations of IGF1 correlating with increased height gain without adverse effects[19]. Regardless, at the

expected first follow-up, a decrease in dosage is recommended if the concentration of IGF1 has increased beyond the normal range, while exploring other possible reasons such as an incorrect diagnosis[16].

[H3] Treatment response. The optimal response to therapy is monitored after the first year via height velocity parameters: these are height velocity and/or change in height SDS that both intrinsically correct for age and sex. Although height velocity is easier to compare with height velocity curves and is more routinely used, height SDS helps assess children with height measurements that fall well below the standard percentile[157,160].

Catch up growth depends on the severity of GHD, with children affected by organic pathologies (hypothalamic-pituitary damage by lesion, surgery, and/or radiation being more likely to show a more marked growth response than children with more moderate forms of IGHD; however, the peak response during a stimulation test in children with IGHD does not seems to predict the degree of catch up growth[162]. Following a year of GH therapy, the medication response is considered poor if the height SDS improvement is lower than 0.4[156,157,160]. The causes behind a low response to therapy include lack of adherence, improper rhGH administration, hypothyroidism, concurrent chronic disease, complete osseous maturation and/or presence of GH antibodies. Some researchers suggest monitoring bone age; however, an issue remains with the inter-observer interpretation of radiographic imaging, and possible GH acceleration of bone maturation before imaging is carried out [163,164]. BoneXpert, an automated method for analysis of hand radiographs of children, has been in use to overcome this issue, yet larger studies are needed to validate its accuracy[165-167].

[H2] Adverse effects

Althoughthe effectiveness of rhGH therapy is undeniable, multiple potential adverse effects need to be monitored. In the short term, intracranial hypertension with increased intraocular pressure, and slipped capital femoral epiphysis**[G]**can arise. Benign intracranial hypertension is to be considered in patients with headache, nausea, visual disturbance and dizziness and should trigger an ophthalmological referral[168]. If confirmed, patients should stop treatment until intracranial pressure is resolved (usually around a month) and then resume at a lower dose. Slipped capital femoral epiphysis and intracranial hypertension are seen more commonly in patients with Turner

syndrome, Prader-Willi syndrome, chronic renal insufficiency and organic GHD than in children with IGHD[169]. Childhood cancer survivors who were previously exposed to total body irradiation are at an increased risk compared with children with other causes of GHD for slipped capital femoral epiphysis during rhGH therapy[170]. For patients who develop this complication, an orthopaedic consultation for pinning of the capital femoral epiphysis should be recommended. Additionally, rhGH treatment can induce a progressive worsening of pre-existing scoliosis, which might require orthopedic intervention. Other rare side effects have been reported, such as transient gynecomastia, increase in growth of non-malignant nevi, carpal tunnel syndrome, arthralgia, oedema, various musculoskeletal comorbidities caused by water and sodium retention, exacerbation of obstructive sleep apnoea due to tonsillar hypertrophy, and pancreatitis. However, the causal relationship between rhGH therapy and these adverse events is yet to be confirmed[171].

[H3] Mortality and risk of malignancy. Assessing mortality in patients with GHD remains difficult owing to the underlying comorbidities leading to GHD. The existing evidence does not support a clear association between GH replacement therapy and risk of death, as has been shown in the Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGhE) study[172-174]. This study assembled cohorts of patients treated in childhood with rhGH in eight European countries since 1984 and followed them for cause-specific mortality and cancer incidence. Although the French report noted concerns regarding the safety of rhGH, with a 33% increase in all-cause mortality and a higher risk of death in patients receiving higher doses (>0.05 mg/kg/day)than lower doses, other reports from the Netherlands, Belgium, and Sweden could not confirm these findings. In the French report, the main causes of mortality were bone tumours and cerebral haemorrhage. The SAGhE study was updated in 2020 with results that showed no significant increase in overall mortality in low-risk patients (those with IGHD or idiopathic short stature)[174]. Conversely, patients with increased risk (those with MPHD and/or comorbidities), showed increased mortality due to cardiovascular and hematological causes that was associated with the underlying conditions[175]. Mortality was not associated with mean daily or cumulative rhGH dose[174]. Similar findings have been reported in other studies[175].

An increased risk of malignancy caused by long-term rhGH treatment in children has been hypothesized. This hypothesis is based on the observation that adults without GHD who have concentrations of IGF1 that fall in the upper quartile show an increased risk of breast and

prostate cancer, possibly due to the growth-promoting effects of GH[176]. However, no report of an increase in new primary malignancies has been noted in any risk factorfree patients (mostly idiopathic GHD) treated with rhGH[16]. Thus, cancer monitoring is not recommended for these patients. For childhood cancer survivors, the correlation between rhGH treatment and secondary cancer is controversial. GH therapy does not increase the re-growth risk of pituitary adenomas or craniopharyngiomas[177]. Irrespectively, in patients with GHD and cancer, waiting for a full year upon completion of cancer therapy to confirm its eradication has been suggested before the initiation of rhGH[21].

[H3] Effects on metabolism. Monitoring of impaired glucose metabolism and potential diabetes mellitus should be considered in patients at risk (predisposed to diabetes via positive family history, small for gestational age, metabolic syndrome, history of gestational diabetes in their mothers)[178]. Furthermore, as GH decreases insulin sensitivity, patients diagnosed with diabetes mellitus might have increased insulin requirements. However, GHD might alter glucose metabolism due to impaired body composition(decreased lean/fat mass ratio), which GH treatment can reverse. Therefore, patients with coexisting or predisposition to diabetes mellitus should not be withheld rhGH treatment. Glycaemic control mightworsen upon the initiation of rhGH treatment, whereas a benefit on glucose metabolism will only be apparent with time after improvement in body composition[179]. For these patients, starting with low doses of rhGH is recommended. Additionally, rhGH can increase T_4 catabolism via the increase in the peripheral conversion of T_4 to T_3, and cortisol catabolism via the inhibition of 11βHSD1 in the conversion of cortisone to cortisol, thereby unveiling central hypothyroidism or hypoadrenalism. Hence, adrenal and thyroid axes should be periodically checked after rhGH therapy is started or the dose is increased, especially in those with structural hypothalamo-pituitary abnormalities and a predisposition to MPHD[180].

[H2] Transitional Care

A period of transition in GHD is a shift between paediatric care to the adult treatment regimen occurring from mid to late teens, up until the mid-twenties. Establishing an appropriate consultation before the end of the paediatric age is essential as the interval between paediatric

care and adult care is often associated with non-attendance and consequent loss to follow up by healthcare professionals[181].

[H3] Persistent or transient GHD. Patients should be categorized according to their risk of persistent GHD. The current guidelines for GH testing during transition all agree on the need of retesting patients with IGHD after stopping rhGH for at least one month[16,182]. However, patients with idiopathic IGHD and an IGF1≥0 SDS probably do not have persistent GHD, and hence transition therapy might not need to be considered[183]. Various causes for normal GH responses upon retesting in IGHD can be hypothesized. Some patients may have a partial GHD, which is sufficient to cause short stature during childhood but does not meet the stricter criteria for diagnosing GHD in adulthood[182]. In others, GHD might have been transient. Additionally, the low reproducibility of provocative tests may have a role. A lack of priming with sex steroids before testing in peripubertal children might also contribute to a discrepancy in testing between childhood and adulthood[183], as can changes in BMI over time. Finally, patients with brain trauma might have transient GHD[184].

Higher likelihood of persistence is seen in patients with an early age at diagnosis, anatomical, organic or genetic causes of GHD, and MPHD. Repeating a GH stimulation test is not necessary for patients with MPHD (≥3 hormonal deficiencies) and/or low-serum IGF1 concentrations (<–2.0 SDS), and/ordocumented genetic defects affecting pituitary function, and/or hypothalamic–pituitary structural brain defects. In these patients, rhGH therapy can be continued without interruption, although the dose needs to be reduced to adult age dosing, which is lower than weight-based childhood dosing[16,182]. In contrast, in patients with a history of brain radiation, GHD might occur up to 10 years after exposure, and therefore these individuals might have GHD despite normal growth[185].

[H3] GH stimulation testing during transition. The guideline for provocative testing varies according to society and government-sponsored guidelines. The insulin tolerance test remains the gold standard. An appropriate hypoglycaemic stimulus is considered when glucose drops below 2.78 mmol/L(50 mg/dL) and is associated with symptoms[16,182]. A peak GH response of <5 μg/L has approximately 95% sensitivity and specificity to detect GHD[186]. This method needs close monitoring as severe neuroglycopaenic symptoms might develop and the test should be

terminated if glycaemia falls below 35 mg/dL. This test is contraindicated in patients with a history of seizures, and cardiovascular or cerebrovascular disease. For these safety concerns, this test has been used less frequently. Depending on the availability, other tests can be used, such as GHRH in combination with arginine, glucagon, or the macimorelin stimulation test[182]. For glucagon, a GH cut-off of <3 μg/L is recommended for normal BMI (18.5-24.9 kg/m^2) and decreases to <1 μg/L with BMI>30 kg/m^{2}and low pretest probability. The cut-off to be used for BMI between 25 and 30 kg/m^2 is controversial. For the GHRH and arginine test, thecut-off peak values vary widely between studies from 5.6 μg/L to 20.3 μg/L, as BMI-adjusted clear cut-offs have not been established yet for adolescents and young adults[187].For the macimorelin-stimulation test, which was approved in 2019, a GH cut-point of 2.8 μg/L was recommended by the FDA[182]. A 2021 report suggests that this test is not influenced by BMI and recommends 5.1 μg/L as the best cut-off [188].

[H3] Treatment with rhGH during transition. Throughout transition, rhGH treatment enables patients to reach an appropriate level of somatic development, induces increases in lean mass, normalizes metabolism and improves quality of life[181,182,186]. Stopping treatment, although not recommended, should be at least accompanied by monitoring GH-dependent endpoints. GHD in adults results in decreased quality of life, increased risk of bone fracture, increased concentrations of LDL-cholesterol and decreased concentrations of HDL-cholesterol[16,181,182,186]. Although some question the efficacy of rhGH for protecting against osteoporosis, most believe that replacement therapy protects against its development[189,190].Similarly, GH is needed for maintaining healthy body composition, as cessation of treatment leads to an increase in visceral adipose tissue mass[191,192]. Changes in body composition in adolescents with severe GHD were demonstrated after only 6 months off therapy, with increased relative and absolute adipose mass, and loss of lean body mass[191]. Standard lipid profiles improve with rhGH, with decreases in total and LDL cholesterol[182,193,194].

In terms of glucose metabolism, the association between type 2 diabetes mellitus (T2DM)and rhGH treatment remains controversial. Untreated patients might be more predisposed to TD2M due to increased visceral adipose tissue mass; however, GH per se is a counter-regulatory hormone as it antagonizes the hepatic and peripheral effects of insulin on glucose metabolism via mechanisms that involve an increase in free fatty acids[182,195-197].

Concerns around the development of T2DM appeared in the KIMS database (Pfizer International Metabolic Database, previously known as Kabi International Metabolic Survey), which showed an increased prevalence ofT2DM, but were invalidated in Hypo-CCS (Eli Lilly Hypopituitary Control and Complications Study) when risk factors such as age, sex, and BMI were accounted for[197,198]. The current evidence does not provide enough data for a causal relationship between rhGH and T2DM[182,184,185,196-199]. If T2DM is suspected throughout treatment, addition and/or adjustment of antidiabetic medications and reduction in rhGH dosing is suggested, although withholding rhGH treatment and focusing on achieving optimal glycaemic control is also a reasonable strategy before resuming rhGH therapy [182].

Although no major cardiac function abnormality has been observed after GH discontinuation, an improvement in markers of endothelial dysfunction and positive effects on left ventricular mass, interventricular septum, diastolic function, and stroke volume index have been reported with rhGH therapy[182,200,201]. However, a 2021 report from a Swedish nationwide cohort with 3,409 adults with IGHD treated with rhGH since childhood showed an increase in the adjusted hazard ratio for all cardiovascular events when compared with individuals matched by age, and sex[202].The reason behind this increase could stem from GH treatment, persistent but untreated GHD in adulthood, other conditions being treated, other potential confounders not captured, or by a combination of the above[203]. Importantly, the consequences of GHD on life expectancy have been questioned by observations in a specific population of patients with IGHD caused by a *GHRHR* mutation. Despite untreated lifetime GHD, these individuals do not have evidence of premature cardiac or cerebrovascular atherosclerosis even at old age while maintaining normal life expectancy[204].

During transition, patients are treated with daily subcutaneous rhGH similarly to the paediatric population. However, as GH secretion varies during a lifetime, the dosing should follow the pattern determined by age and sex, along with any comorbidities and oestrogen status[16,182]. For patients younger than 30 years, most guidelines recommend initiating a dose of 400–500 µg/day, with a mildly increased dose during transition, that is,an increase in daily dosing by 100–200 µg/day every 1–2 months based on the individual's response[16,182]. Dosage of long-acting preparations will depend on the specific formulation. Importantly, women might need a higher dose than men, especially if receiving oral oestrogens, due to a first-pass effect in the liver, which renders the organ GH resistant. For this reason, oestrogen replacement is

recommended to be administered via transdermal patch in women on GH replacement. In terms of GHD aetiology, no difference between childhood-onset and adult-onset exists in rhGH dosing.

During transition, serum concentrations of IGF1 should be monitored every 4 to 6 weeks until the optimal maintenance dose of rhGH is achieved. A repeat follow-up IGF1 should be measured every 6 to 12 months. No consensus exists on the optimal target IGF1 concentration; however, in general, the goal is maintaining a concentration within age-specific and sex-specific normal ranges. As previously mentioned, serum concentrations of IGF1 in high quartiles have been associated with increased risk of certain malignancies in population studies, therefore, keeping IGF1 in the mid, rather than high–normal range, seems advisable. By using reduced GH dosages, such an approach could also limit the cost of therapy for health systems. In the future, the development of an index that would more closely correlate with long-term outcomes (such as HbA_{1C} in diabetes mellitus) would be ideal for adjusting GH dosing in young adults, in whom growth cannot be used as the ultimate measure.

[H1] Conclusions

In conclusion, great advances have been made in the past decades in refining the diagnosis and determining the causes of childhood GHD, while optimizing its treatment. The contribution of neuroimaging has led to the identification of specific pituitary and brain abnormalities. This advance has enabled the characterization of patients to be screened for additional pituitary deficiencies, those who might need GH replacement in adult life and those worthy of molecular studies and genetic counselling. Along with new technologies such as next-generation and possibly whole-genome sequencing, improvement of the molecular diagnostic process progresses at an impressive pace. Various questions remain that need to be answered, including the variable penetrance of genetic mutations, the considerable phenotypic variability, the role of environmental factors, and the interaction between candidate genes, which suggests a notable role of digenicity or oligogenicity. The development of therapeutic long-acting GH preparations holds the promise of being an effective treatment that overcomes the problems of poor adherence associated with the burden of daily injections. Long-acting GH preparations, thus, might have different effects on efficacy, metabolism and safety; with the latter factor still a matter of investigation, particularly in patients treated with high doses. The problems associated with the poor reproducibility of GH stimulation tests are yet partially unsolved and remain a major

challenge in diagnosing GHD, particularly in children with IGHD, although our knowledge on GH secretory dynamics has considerably expanded in the last decades. The relative importance of MRI and a molecular diagnosis in these patients might be particularly worth pursuing.

Key points:

I. *Diagnosis*

- Growth Hormone (GH) affectsgrowth, body composition, metabolic profile, bone mineral density, and quality of life. A secretory defect leads to impaired growth and function, known as GH deficiency (GHD).
- This can occur in isolation (isolated GHD, IGHD) or conjunction with other pituitary hormone deficits (multiple pituitary hormone deficiency, MPHD). GHD may be congenital (genetic defects, intracranial malformations, prenatal infection) or acquired (trauma, tumors, radiation, inflammation, central nervous system infections, vascular events).

II. *Genetic Diagnosis of Growth Hormone Deficiency*

- 3-30% of GHD cases are familial. In IGHD,the most commonly mutated genes are the GH gene (*GH1*) or the GHRH receptor (*GHRHR*) gene while MPHD can be caused by mutations in several pituitary-specific transcription factors.

III. *Neuroimaging in Hypopituitarism*

- Congenital hypothalamic-pituitary abnormalities confirmed via imaging, such as anterior pituitary hypoplasia, pituitary stalk anomalies, and ectopic posterior pituitary, are common in both children with moderate to severe IGHD and those with MPHD.

IV. *Treatment, Outcome & Transition*

- Recombinant Human GH (rhGH), 0.16-0.24 mg/kg/week, is the treatment in children with GHD. It is best when initiated upon diagnosis and adjusted by serum IGF-1 concentrations, height velocity, and bone age.
- Transitional care is the shift from pediatric care to adult treatment that provides full-body maturation, metabolic control, and improved quality of life for those at risk of persistent GHD.

References

1. Kelberman, D., Rizzoti, K., Lovell-Badge, R., Robinson, I. C. & Dattani, M. T. Genetic regulation of pituitary gland development in human and mouse. *Endocr Rev* **30**, 790-829 (2009).

2. Fang, Q. *et al.* Genetics of Combined Pituitary Hormone Deficiency: Roadmap into the Genome Era. *Endocr Rev* **37**, 636-675 (2016).

3. Schilbach, K. & Bidlingmaier, M. Laboratory investigations in the diagnosis and follow-up of GH-related disorders. *Arch Endocrinol Metab* **63**, 618-629 (2019).

4. Dehkhoda, F., Lee, C. M. M., Medina, J. & Brooks, A. J. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. *Front Endocrinol (Lausanne)* **9**, 35 (2018).

5. Bach, L. A. 40 YEARS OF IGF1: IGF-binding proteins. *Journal of Molecular Endocrinology* **61**, T11-T28 (2018).

6. Blum, W. F. *et al.* The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. *Endocr Connect* **7**, R212-R222 (2018).

7. Støving, R. K., Hangaard, J., Hagen, C. & Flyvbjerg, A. Low levels of the 150-kD insulin-like growth factor binding protein 3 ternary complex in patients with anorexia nervosa: effect of partial weight recovery. *Horm Res* **60**, 43-48 (2003).

8. Society, G. H. R. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. *J Clin Endocrinol Metab* **85**, 3990-3993 (2000).

9. Sobrier, M. L. *et al.* Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities. *J Clin Endocrinol Metab* **91**, 4528-4536 (2006).

10. Garavelli, L. *et al.* Solitary median maxillary central incisor syndrome: clinical case with a novel mutation of sonic hedgehog. *Am J Med Genet A* **127A**, 93-95 (2004).

11. Secco, A. *et al.* The glucagon test in the diagnosis of growth hormone deficiency in children with short stature younger than 6 years. *J Clin Endocrinol Metab* **94**, 4251-4257 (2009).

12. Flavelle, S. & Cummings, E. Case 2: An unusual case of delayed puberty. *Paediatr Child Health* **17**, 505-507 (2012).

13. Taylor, M. *et al.* Hypothalamic-pituitary lesions in pediatric patients: endocrine symptoms often precede neuro-ophthalmic presenting symptoms. *J Pediatr* **161**, 855-863 (2012).

14. El Kholy, M. *et al.* Normal Growth despite Combined Pituitary Hormone Deficiency. *Horm Res Paediatr* **92**, 133-142 (2019).

15. Binder, G. *et al.* Diagnosis of severe growth hormone deficiency in the newborn. *Clin Endocrinol (Oxf)* **93**, 305-311 (2020).

16. Grimberg, A. *et al.* Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. *Horm Res Paediatr* **86**, 361-397 (2016).

17. Mamilly, L., Pyle-Eilola, A. L., Chaudhari, M. & Henry, R. K. The utility of a random growth hormone level in determining neonatal growth hormone sufficiency. *Clin Endocrinol (Oxf)* **94**, 392-398 (2020).

18. Kelly, A., Tang, R., Becker, S. & Stanley, C. A. Poor specificity of low growth hormone and cortisol levels during fasting hypoglycemia for the diagnoses of growth hormone deficiency and adrenal insufficiency. *Pediatrics* **122**, e522-528 (2008).

19. Cohen, P. *et al.* Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. *J Clin Endocrinol Metab* **93**, 4210-4217 (2008).

20. Binder, G. *et al.* GHD Diagnostics in Europe and the US: An Audit of National Guidelines and Practice. *Horm Res Paediatr* **92**, 150-156 (2019).

21. Juul, A. *et al.* European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. *Horm Res* **58**, 233-241 (2002).

22. Murray, P. G., Dattani, M. T. & Clayton, P. E. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. *Arch Dis Child* **101**, 96-100 (2016).

23. Rosenfeld, R. G. Is growth hormone deficiency a viable diagnosis? *J Clin Endocrinol Metab* **82**, 349-351 (1997).

24. Loche, S. *et al.* Effect of body mass index on the growth hormone response to clonidine stimulation testing in children with short stature. *Clin Endocrinol (Oxf)* **74**, 726-731 (2011).

25. Meinhardt, U. J. & Ho, K. K. Modulation of growth hormone action by sex steroids. *Clin Endocrinol (Oxf)* **65**, 413-422 (2006).

26. Martin, L. G. *et al.* Effect of androgen on growth hormone secretion and growth in boys with short stature. *Acta Endocrinol (Copenh)* **91**, 201-212 (1979).

27. Galazzi, E. *et al.* Clinical benefits of sex steroids given as a priming prior to GH provocative test or as a growth-promoting therapy in peripubertal growth delays: Results of a retrospective study among ENDO-ERN centres. *Clin Endocrinol (Oxf)* **94**, 219-228 (2021).

28. Clemmons, D. R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. *Clin Chem* **57**, 555-559 (2011).

29. Binder, G., Huller, E., Blumenstock, G. & Schweizer, R. Auxology-based cut-off values for biochemical testing of GH secretion in childhood. *Growth Horm IGF Res* **21**, 212-218 (2011).

30. Guzzetti, C. *et al.* Cut-off limits of the peak GH response to stimulation tests for the diagnosis of GH deficiency in children and adolescents: study in patients with organic GHD. *Eur J Endocrinol* **175**, 41-47 (2016).

31. Manolopoulou, J. *et al.* Automated 22-kD growth hormone-specific assay without interference from Pegvisomant. *Clin Chem* **58**, 1446-1456 (2012).

32. Shen, Y. *et al.* Diagnostic value of serum IGF-1 and IGFBP-3 in growth hormone deficiency: a systematic review with meta-analysis. *Eur J Pediatr* **174**, 419-427 (2015).
33. Ibba, A. *et al.* IGF1 for the diagnosis of growth hormone deficiency in children and adolescents: a reappraisal. *Endocr Connect* **9**, 1095-1102 (2020).

34. Felício, J. S. *et al.* Diagnosis of Idiopathic GHD in Children Based on Response to rhGH Treatment: The Importance of GH Provocative Tests and IGF-1. *Front Endocrinol (Lausanne)* **10**, 638 (2019).

35. Hadjadj, S. *et al.* Diagnostic strategy for growth hormone deficiency: relevance of IGF-1 determination as a screening test. *Ann Endocrinol (Paris)* **68**, 449-455 (2007).

36. Ranke, M. B. *et al.* Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. *Horm Res* **55**, 115-124 (2001).

37. Mavromati, M. *et al.* Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. *J Clin Endocrinol Metab* **102**, 2844-2852 (2017).

38. Hjortebjerg, R. & Frystyk, J. Determination of IGFs and their binding proteins. *Best Pract Res Clin Endocrinol Metab* **27**, 771-781 (2013).

39. Bidlingmaier, M. *et al.* Reference intervals for insulin-like growth factor-1 (IGF-1) from birth to senescence: results from a multicenter study using a new automated

chemiluminescence IGF-I immunoassay conforming to recent international recommendations. *J Clin Endocrinol Metab* **99**, 1712-1721 (2014).

40. Choi, Y. J. *et al.* Discriminatory performance of insulin-like growth factor 1 and insulin-like growth factor binding protein-3 by correlating values to chronological age, bone age, and pubertal status for diagnosis of isolated growth hormone deficiency. *Ann Pediatr Endocrinol Metab* **25**, 240-247 (2020).

41. Inoue-Lima, T. H. *et al.* IGF-1 assessed by pubertal status has the best positive predictive power for GH deficiency diagnosis in peripubertal children. *J Pediatr Endocrinol Metab* **32**, 173-179 (2019).

42. Löfqvist, C. *et al.* Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. *J Clin Endocrinol Metab* **90**, 1420-1427 (2005).

43. Friedrich, N. *et al.* Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. *J Clin Endocrinol Metab* **99**, 1675-1686 (2014).

44. Tillmann, V. *et al.* Serum insulin-like growth factor-I, IGF binding protein-3 and IGFBP-3 protease activity after cranial irradiation. *Horm Res* **50**, 71-77(1998).

45. Morrison, K. M. *et al.* Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly. *Eur J Endocrinol* **156**, 331-339 (2007).

46. De Rienzo, F. *et al.* Frequency of genetic defects in combined pituitary hormone deficiency: a systematic review and analysis of a multicentre Italian cohort. *Clin Endocrinol (Oxf)* **83**, 849-860 (2015).

47. Alatzoglou, K. S. *et al.* Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. *J Clin Endocrinol Metab* **94**, 3191-3199 (2009).

48. Wagner, J. K., Eblé, A., Hindmarsh, P. C. & Mullis, P. E. Prevalence of human GH-1 gene alterations in patients with isolated growth hormone deficiency. *Pediatr Res* **43**, 105-110 (1998).

49. Alatzoglou, K. S. & Dattani, M. T. Genetic causes and treatment of isolated growth hormone deficiency-an update. *Nat Rev Endocrinol* **6**, 562-576 (2010).

50. Niall, H. D. Revised primary structure for human growth hormone. *Nat New Biol* **230**, 90-91(1971).

51. Ghizzoni, L. *et al.* Isolated growth hormone deficiency type IA associated with a 45-kilobase gene deletion within the human growth hormone gene cluster in an Italian family. *Pediatr Res* **36**, 654-659 (1994).

52. Goossens, M., Brauner, R., Czernichow, P., Duquesnoy, P. & Rappaport, R. Isolated growth hormone (GH) deficiency type 1A associated with a double deletion in the human GH gene cluster. *J Clin Endocrinol Metab* **62**, 712-716 (1986).

53. Kamijo, T. & Phillips, J. A. Detection of molecular heterogeneity in GH-1 gene deletions by analysis of polymerase chain reaction amplification products. *J Clin Endocrinol Metab* **74**, 786-789 (1992).

54. Cogan, J. D. *et al.* Heterogeneous growth hormone (GH) gene mutations in familial GH deficiency. *J Clin Endocrinol Metab* **76**, 1224-1228 (1993).

55. Iughetti, L. *et al.* Complex disease phenotype revealed by GH deficiency associated with a novel and unusual defect in the GH-1 gene. *Clin Endocrinol (Oxf)* **69**, 170-172 (2008).

56. Hamid, R. *et al.* A molecular basis for variation in clinical severity of isolated growth hormone deficiency type II. *J Clin Endocrinol Metab* **94**, 4728-4734 (2009).

57. Hess, O. *et al.* Variable phenotypes in familial isolated growth hormone deficiency caused by a G6664A mutation in the GH-1 gene. *J Clin Endocrinol Metab* **92**, 4387-4393 (2007).

58. Binder, G., Nagel, B. H., Ranke, M. B. & Mullis, P. E. Isolated GH deficiency (IGHD) type II: imaging of the pituitary gland by magnetic resonance reveals characteristic differences in comparison with severe IGHD of unknown origin. *Eur J Endocrinol* **147**, 755-760 (2002).

59. Salemi, S. *et al.* Isolated autosomal dominant growth hormone deficiency: stimulating mutant GH-1 gene expression drives GH-1 splice-site selection, cell proliferation, and apoptosis. *Endocrinology* **148**, 45-53 (2007).

60. Turton, J. P., Buchanan, C. R., Robinson, I. C., Aylwin, S. J. & Dattani, M. T. Evolution of gonadotropin deficiency in a patient with type II autosomal dominant GH deficiency. *Eur J Endocrinol* **155**, 793-799 (2006).

61. Petkovic, V. *et al.* GH mutant (R77C) in a pedigree presenting with the delay of growth and pubertal development: structural analysis of the mutant and evaluation of the biological activity. *Eur J Endocrinol* **157 Suppl 1**, S67-74 (2007).

62. Takahashi, Y. *et al.* Short stature caused by a mutant growth hormone with an antagonistic effect. *Endocr J* **43 Suppl**, S27-32s27 (1996).

63. Alba, M. & Salvatori, R. Naturally-occurring missense mutations in the human growth hormone-releasing hormone receptor alter ligand binding. *J Endocrinol* **186**, 515-521 (2005).

64. Godi, M. *et al.* A recurrent signal peptide mutation in the growth hormone releasing hormone receptor with defective translocation to the cell surface and isolated growth hormone deficiency. *J Clin Endocrinol Metab* **94**, 3939-3947 (2009).

65. Demirbilek, H. *et al.* Familial isolated growth hormone deficiency due to a novel homozygous missense mutation in the growth hormone releasing hormone receptor gene: clinical presentation with hypoglycemia. *J Clin Endocrinol Metab* **99**, E2730-2734 (2014).

66. Gregory, L. C. *et al.* Partial Loss of Function of the GHRH Receptor Leads to Mild Growth Hormone Deficiency. *J Clin Endocrinol Metab* **101**, 3608-3615 (2016).

67. Zizzari, P. *et al.* Endogenous ghrelin regulates episodic growth hormone (GH) secretion by amplifying GH Pulse amplitude: evidence from antagonism of the GH secretagogue-R1a receptor. *Endocrinology* **146**, 3836-3842 (2005).

68. Pantel, J. *et al.* Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. *J Clin Invest* **116**, 760-768 (2006).

69. Pantel, J. *et al.* Recessive isolated growth hormone deficiency and mutations in the ghrelin receptor. *J Clin Endocrinol Metab* **94**, 4334-4341 (2009).

70. Argente, J. *et al.* Defective minor spliceosome mRNA processing results in isolated familial growth hormone deficiency. *EMBO Mol Med* **6**, 299-306 (2014).

71. Verberne, E. A., Faries, S., Mannens, M. M. A. M., Postma, A. V. & van Haelst, M. M. Expanding the phenotype of biallelic RNPC3 variants associated with growth hormone deficiency. *Am J Med Genet A* **182A**, 1952-1956 (2020).

72. Cogan, J. D. *et al.* The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. *J Clin Endocrinol Metab* **83**, 3346-3349 (1998).

73. Deladoëy, J. *et al.* "Hot spot" in the PROP1 gene responsible for combined pituitary hormone deficiency. *J Clin Endocrinol Metab* **84**, 1645-1650 (1999).

74. Ward, R. D. *et al.* Role of PROP1 in pituitary gland growth. *Mol Endocrinol* **19**, 698-710 (2005).

75. Riepe, F. G. *et al.* Longitudinal imaging reveals pituitary enlargement preceding hypoplasia in two brothers with combined pituitary hormone deficiency attributable to PROP1 mutation. *J Clin Endocrinol Metab* **86**, 4353-4357 (2001).

76. Voutetakis, A. *et al.* Pituitary magnetic resonance imaging in 15 patients with Prop1 gene mutations: pituitary enlargement may originate from the intermediate lobe. *J Clin Endocrinol Metab* **89**, 2200-2206 (2004).

77. Radovick, S. *et al.* A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. *Science* **257**, 1115-1118 (1992).

78. Cohen, R. N. *et al.* The role of CBP/p300 interactions and Pit-1 dimerization in the pathophysiological mechanism of combined pituitary hormone deficiency. *J Clin Endocrinol Metab* **91**, 239-247 (2006).

79. Hoppmann, J. *et al.* Novel Variants in the POU1F1 Beta Isoform are Associated with Isolated Growth Hormone Deficiency and Combined Pituitary Hormone Deficiency. *57th Annual ESPE* **89**(2018).

80. Kale, S. *et al.* Genetic spectrum and predictors of mutations in four known genes in Asian Indian patients with growth hormone deficiency and orthotopic posterior pituitary: an emphasis on regional genetic diversity. *Pituitary* **23,** 701-715 (2020).

81. Bashamboo, A., Bignon-Topalovic, J., Rouba, H., McElreavey, K. & Brauner, R. A Nonsense Mutation in the Hedgehog Receptor CDON Associated With Pituitary Stalk Interruption Syndrome. *J Clin Endocrinol Metab* **101**, 12-15 (2016).

82. Bashamboo, A., Bignon-Topalovic, J., Moussi, N., McElreavey, K. & Brauner, R. Mutations in the Human ROBO1 Gene in Pituitary Stalk Interruption Syndrome. *J Clin Endocrinol Metab* **102**, 2401-2406 (2017).

83. Giri, D. *et al.* Novel FOXA2 mutation causes Hyperinsulinism, Hypopituitarism with Craniofacial and Endoderm-derived organ abnormalities. *Hum Mol Genet* **26**, 4315-4326 (2017).

84. Karaca, E. *et al.* Whole-exome sequencing identifies homozygous GPR161 mutation in a family with pituitary stalk interruption syndrome. *J Clin Endocrinol Metab* **100**, E140-147 (2015).

85. Webb, E. A. & Dattani, M. T. Septo-optic dysplasia. *Eur J Hum Genet* **18**, 393-397 (2010).

86. Morishima, A. & Aranoff, G. S. Syndrome of septo-optic-pituitary dysplasia: the clinical spectrum. *Brain Dev* **8**, 233-239 (1986).

87. Mehta, A. *et al.* Congenital hypopituitarism: clinical, molecular and neuroradiological correlates. *Clin Endocrinol (Oxf)* **71**, 376-382 (2009).

88. Dattani, M. T. *et al.* Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. *Nat Genet* **19**, 125-133 (1998).

89. Gaston-Massuet, C. *et al.* Transcription factor 7-like 1 is involved in hypothalamo-pituitary axis development in mice and humans. *Proc Natl Acad Sci U S A* **113**, E548-557 (2016).

90. Patel, L., McNally, R. J., Harrison, E., Lloyd, I. C. & Clayton, P. E. Geographical distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest England. *J Pediatr* **148**, 85-88 (2006).

91. Cerbone, M., Güemes, M., Wade, A., Improda, N. & Dattani, M. Endocrine morbidity in midline brain defects: Differences between septo-optic dysplasia and related disorders. *EClinicalMedicine* **19**, 100224 (2020).

92. Kelberman, D. *et al.* Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. *J Clin Invest* **116**, 2442-24558 (2006).

93. Macchiaroli, A. *et al.* A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. *Gene* **534**, 282-285 (2014).

94. Sisodiya, S. M. *et al.* Role of SOX2 mutations in human hippocampal malformations and epilepsy. *Epilepsia* **47**, 534-542 (2006).

95. Tajima, T. *et al.* OTX2 loss of function mutation causes anophthalmia and combined pituitary hormone deficiency with a small anterior and ectopic posterior pituitary. *J Clin Endocrinol Metab* **94**, 314-319 (2009).

96. Gregory, L.C. *et al*. The phenotypic spectrum associated with OTX2 mutations in humans. *Eur J Endocrinol* **185, 121-135** (2021).

97. Brachet, C. *et al.* Truncating RAX Mutations: Anophthalmia, Hypopituitarism, Diabetes Insipidus, and Cleft Palate in Mice and Men. *J Clin Endocrinol Metab* **104**, 2925-2930(2019).

98. Alatzoglou, K. S. *et al.* SOX3 deletion in mouse and human is associated with persistence of the craniopharyngeal canal. *J Clin Endocrinol Metab* **99**, E2702-2708(2014).

99. Laumonnier, F. *et al.* Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. *Am J Hum Genet* **71**, 1450-1455 (2002).

100. Woods, K. S. *et al.* Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. *Am J Hum Genet* **76**, 833-849 (2005).

101. Castinetti, F. *et al.* A novel dysfunctional LHX4 mutation with high phenotypical variability in patients with hypopituitarism. *J Clin Endocrinol Metab* **93**, 2790-2799 (2008).

102. Pfaeffle, R. W. *et al.* Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. *J Clin Endocrinol Metab* **92**, 1909-1919 (2007).

103. Rajab, A. *et al.* Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss. *Hum Mol Genet* **17**, 2150-2159 (2008).

104. Gregory, L. C. *et al.* Novel Lethal Form of Congenital Hypopituitarism Associated With the First Recessive LHX4 Mutation. *J Clin Endocrinol Metab* **100**, 2158-2164 (2015).

105. Hufnagel, R. B. *et al.* Neuropathy target esterase impairments cause Oliver-McFarlane and Laurence-Moon syndromes. *J Med Genet* **52**, 85-94 (2015).

106. McCabe, M. J. *et al.* Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. *J Clin Endocrinol Metab* **96**, E1709-1718 (2011).

107. Roessler, E. *et al.* Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features. *Proc Natl Acad Sci U S A* **100**, 13424-13429 (2003).

108. Tatsi, C. *et al.* Pituitary stalk interruption syndrome and isolated pituitary hypoplasia may be caused by mutations in holoprosencephaly-related genes. *J Clin Endocrinol Metab* **98**, E779-784 (2013).

109. Gregory, L. C. & Dattani, M. T. The Molecular Basis of Congenital Hypopituitarism and Related Disorders. *J Clin Endocrinol Metab* **105**, E2103-2120 (2020).

110. Correa, F. A. *et al.* FGFR1 and PROKR2 rare variants found in patients with combined pituitary hormone deficiencies. *Endocr Connect* **4**, 100-107 (2015).

111. Raivio, T. *et al.* Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. *J Clin Endocrinol Metab* **97**, E694-699(2012).

112. Martín, M. G. *et al.* Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. *Gastroenterology* **145**, 138-148 (2013).

113. Hughes, J. N. *et al.* Identification of an IGSF1-specific deletion in a five-generation pedigree with X-linked Central Hypothyroidism without macroorchidism. *Clin Endocrinol (Oxf)* **85**, 609-615 (2016).

114. Di Iorgi, N. *et al.* The use of neuroimaging for assessing disorders of pituitary development. *Clin Endocrinol (Oxf)* **76**, 161-176 (2012).

115. Vergier, J. *et al.* DIAGNOSIS OF ENDOCRINE DISEASE: Pituitary stalk interruption syndrome: etiology and clinical manifestations. *Eur J Endocrinol* **181**, R199-R209 (2019).

116. Cohen, E. *et al.* Contribution of LHX4 Mutations to Pituitary Deficits in a Cohort of 417 Unrelated Patients. *J Clin Endocrinol Metab* **102**, 290-301 (2017).

117. Deal, C. *et al.* Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study. *Horm Res Paediatr* **79**, 283-292 (2013).

118. Wang, C. Z. *et al.* Pituitary Stalk Interruption Syndrome: From Clinical Findings to Pathogenesis. *J Neuroendocrinol* **29**12451 (2017).

119. Di Iorgi, N. *et al.* Classical and non-classical causes of GH deficiency in the paediatric age. *Best Pract Res Clin Endocrinol Metab* **30**, 705-736 (2016).

120. Maghnie, M., Lindberg, A., Koltowska-Häggström, M. & Ranke, M. B. Magnetic resonance imaging of CNS in 15,043 children with GH deficiency in KIGS (Pfizer International Growth Database). *Eur J Endocrinol* **168**, 211-217 (2013).

121. Blum, W. F. *et al.* Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary development and GH secretion: Frequencies, phenotypes and growth outcomes. *EBioMedicine* **36**, 390-400 (2018).

122. McCormack, S. E. *et al.* Digenic Inheritance of PROKR2 and WDR11 Mutations in Pituitary Stalk Interruption Syndrome. *J Clin Endocrinol Metab* **102**, 2501-2507 (2017).

123. David, O. *et al.* Pituitary stalk interruption syndrome broadens the clinical spectrum of the TTC26 ciliopathy. *Clin Genet* **98**, 303-307 (2020).

124. Guo, Q. H. *et al.* Multi-genic pattern found in rare type of hypopituitarism: a whole-exome sequencing study of Han Chinese with pituitary stalk interruption syndrome. *J Cell Mol Med* **21**, 3626-3632 (2017).

125. Johnson-Tesch, B. A., Gawande, R. S., Zhang, L., MacMillan, M. L. & Nascene, D. R. Fanconi anemia: correlating central nervous system malformations and genetic complementation groups. *Pediatr Radiol* **47**, 868-876 (2017).

126. Zwaveling-Soonawala, N. *et al.* Clues for Polygenic Inheritance of Pituitary Stalk Interruption Syndrome From Exome Sequencing in 20 Patients. *J Clin Endocrinol Metab* **103**, 415-428 (2018).

127. Lodge, E. J. *et al.* Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development. *JCI Insight* **5**, e134310 (2020).

128. Argyropoulou, M. I. & Kiortsis, D. N. MRI of the hypothalamic-pituitary axis in children. *Pediatr Radiol* **35**, 1045-1055 (2005).

129. Sari, S. *et al.* Measures of pituitary gland and stalk: from neonate to adolescence. *J Pediatr Endocrinol Metab* **27**, 1071-1076(2014).

130. Godano, E. *et al.* Role of MRI T2-DRIVE in the assessment of pituitary stalk abnormalities without gadolinium in pituitary diseases. *Eur J Endocrinol* **178**, 613-622 (2018).

131. Severino, M. *et al.* Midbrain-hindbrain involvement in septo-optic dysplasia. *AJNR Am J Neuroradiol* **35**, 1586-1592 (2014).

132. Lenz, A. M. & Root, A. W. Empty sella syndrome. *Pediatr Endocrinol Rev* **9**, 710-715 (2012).

133. Cacciari, E. et al. Empty sella in children and adolescents with possible hypothalamic-pituitary disorders. *J Clin Endocrinol Metab* **78**, 767-771 (1994).

134. Scala, M. *et al.* Familial ROBO1 deletion associated with ectopic posterior pituitary, duplication of the pituitary stalk and anterior pituitary hypoplasia. *J Pediatr Endocrinol Metab* **32**, 95-99 (2019).

135. Netchine, I. *et al.* Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. *Nat Genet* **25**, 182-186 (2000).

136. Ybarra, M. *et al.* A new imaging entity consistent with partial ectopic posterior pituitary gland: report of six cases. *Pediatr Radiol* **50**, 107-115 (2020).

137. Campbell, H. J. & Harris, G. W. The volume of the pituitary and mehypothalamic nerve fibers in the neurohypophysis after pituitary stalk section in the ferret. *J Comp Neurol* **135**, 121-144 (1969).

138. Adams, J. H., Daniel, P. M. & Prichard, M. M. Degeneration and regeneration of hypothalamic nerve fibers in the neurohypophysis after pituitary stalk section in the ferret. *J Comp Neurol* **135**, 121-144 (1969).

139. Surtees, R., Adams, J., Price, D., Clayton, P. & Shalet, S. Association of adverse perinatal events with an empty sella turcica in children with growth hormone deficiency. *Horm Res* **28**, 5-12 (1987).

140. Maghnie, M. *et al.* Hypothalamic-pituitary dysfunction in growth hormone-deficient patients with pituitary abnormalities. *J Clin Endocrinol Metab* **73**, 79-83 (1991).

141. Pinto, G. *et al.* Pituitary stalk interruption syndrome: a clinical-biological-genetic assessment of its pathogenesis. *J Clin Endocrinol Metab* **82**, 3450-3454 (1997).

142. Lubinsky, M. S. Hypothesis: septo-optic dysplasia is a vascular disruption sequence. *Am J Med Genet* **69**, 235-236 (1997).

143. Maghnie, M., Larizza, D., Zuliani, I. & Severi, F. Congenital central nervous system abnormalities, idiopathic hypopituitarism and breech delivery: what is the connection? *Eur J Pediatr* **152**, 175 (1993).

144. Fujita, K. *et al.* The association of hypopituitarism with small pituitary, invisible pituitary stalk, type 1 Arnold-Chiari malformation, and syringomyelia in seven patients born in breech position: a further proof of birth injury theory on the pathogenesis of "idiopathic hypopituitarism". *Eur J Pediatr* **151**, 266-270 (1992).

145. Parks, J. S. Congenital Hypopituitarism. *Clin Perinatol* **45**, 75-91001 (2018).

146. Murray, P. G. *et al.* Likelihood of persistent GH deficiency into late adolescence: relationship to the presence of an ectopic or normally sited posterior pituitary gland. *Clin Endocrinol (Oxf)* **71**, 215-219 (2009).

147. Binder, G. *et al.* Evolving pituitary hormone deficits in primarily isolated GHD: a review and experts' consensus. *Mol Cell Pediatr* **7**, 16 (2020).

148. Maghnie, M. *et al.* Dynamic MRI in the congenital agenesis of the neural pituitary stalk syndrome: the role of the vascular pituitary stalk in predicting residual anterior pituitary function. *Clin Endocrinol (Oxf)* **45**, 281-290 (1996).

149. Zenaty, D., Garel, C., Limoni, C., Czernichow, P. & Léger, J. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency. *Clin Endocrinol (Oxf)* **58**, 647-652 (2003).

150. Richmond, E. & Rogol, A. D. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. *Best Pract Res Clin Endocrinol Metab* **30**, 749-755 (2016).

151. Lal, R. A. & Hoffman, A. R. Perspectives on long-acting growth hormone therapy in children and adults. *Arch Endocrinol Metab* **63**, 601-607 (2019).

152. Miller, B. S., Velazquez, E. & Yuen, K. C. J. Long-Acting Growth Hormone Preparations - Current Status and Future Considerations. *J Clin Endocrinol Metab* **105**, (2020).

153. Yuen, K. C. J., Miller, B. S. & Biller, B. M. K. The current state of long-acting growth hormone preparations for growth hormone therapy. *Curr Opin Endocrinol Diabetes Obes* **25**, 267-273 (2018).

154. Johannsson, G. *et al.* Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial. *J Clin Endocrinol Metab* **105**, E1358-1376 (2020).

155. Yang, Y. *et al.* Efficacy and safety of long-acting growth hormone in children with short stature: a systematic review and meta-analysis. *Endocrine* **65**, 25-34(2019).

156. Ranke, M. B. & Lindberg, A. Predicting growth in response to growth hormone treatment. *Growth Horm IGF Res* **19**, 1-11 (2009).

157. Bakker, B., Frane, J., Anhalt, H., Lippe, B. & Rosenfeld, R. G. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. *J Clin Endocrinol Metab* **93**, 352-357 (2008).

158. Bang, P. *et al.* A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. *Horm Res Paediatr* **75**, 335-345 (2011).

159. Pozzobon, G. *et al.* Growth hormone therapy in children: predictive factors and short-term and long-term response criteria. *Endocrine* **66**, 614-621 (2019).

160. Ranke, M. B., Lindberg, A. & Board, K. I. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. *J Clin Endocrinol Metab* **95**, 1229-1237 (2010).

161. Kriström, B. *et al.* Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. *J Clin Endocrinol Metab* **94**, 483-490 (2009).

162. Carrascosa, A. *et al.* Growth hormone secretory status evaluated by growth hormone peak after two pharmacological growth hormone release stimuli did not significantly influence the two-year catch-up growth induced by growth hormone therapy in 318 prepubertal short children with idiopathic growth retardation. *Horm Res Paediatr* **75**, 106-114 (2011).

163. Kaufman, F. R. & Sy, J. P. Regular monitoring of bone age is useful in children treated with growth hormone. *Pediatrics* **104**, 1039-1042 (1999).

164. Wilson, D. M. Regular monitoring of bone age is not useful in children treated with growth hormone. *Pediatrics* **104**, 1036-1039 (1999).

165. Martin, D. D., Sato, K., Sato, M., Thodberg, H. H. & Tanaka, T. Validation of a new method for automated determination of bone age in Japanese children. *Horm Res Paediatr* **73**, 398-404 (2010).

166. Martin, D. D., Schittenhelm, J. & Thodberg, H. H. Validation of adult height prediction based on automated bone age determination in the Paris Longitudinal Study of healthy children. *Pediatr Radiol* **46**, 263-269 (2016).

167. Pinsker, J. E. *et al.* Automated Bone Age Analysis with Lossy Image Files. *Mil Med* **182**, e1769-e1772 (2017).

168. Crock, P. A. *et al.* Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand. *Acta Paediatr* **87**, 381-386 (1998).

169. Darendeliler, F., Karagiannis, G. & Wilton, P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. *Horm Res* **68 Suppl 5**, 41-47 (2007).

170. Mostoufi-Moab, S. *et al.* Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy. *Pediatr Blood Cancer* **60**, 1766-1771 (2013).

171. Miller, B. S. & Rosenfeld, R. G. Monitoring rhGH Safety: rhGH Registries, SAGhE and Future Needs. *Pediatr Endocrinol Rev* **16**, 150-161 (2018).

172. Carel, J. C. *et al.* Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. *J Clin Endocrinol Metab* **97**, 416-425 (2012).

173. Sävendahl, L. *et al.* Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. *J Clin Endocrinol Metab* **97**, E213-217 (2012).

174. Sävendahl, L. *et al.* Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. *Lancet Diabetes Endocrinol* **8**, 683-692 (2020).

175. Albertsson-Wikland, K. *et al.* Mortality Is Not Increased in Recombinant Human Growth Hormone-treated Patients When Adjusting for Birth Characteristics. *J Clin Endocrinol Metab* **101**, 2149-2159 (2016).

176. Boguszewski, C. L. & Boguszewski, M. C. D. S. Growth Hormone's Links to Cancer. *Endocr Rev* **40**, 558-574 (2019).

177. Losa, M. et al. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence. *J Clin Endocrinol Metab* **105**, 1573-1580 (2020).

178. Raman, S. *et al.* Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee. *J Clin Endocrinol Metab* **100**, 2192-2203 (2015).

179. Grimberg, A. & Allen, D. B. Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. *Curr Opin Pediatr* **29**, 466-471 (2017).

180. Abs, R. *et al.* Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. *Eur J Endocrinol* **168**, 297-305 (2013).

181. Downing, J. *et al.* Transition in endocrinology: the challenge of maintaining continuity. *Clin Endocrinol (Oxf)* **78**, 29-35 (2013).

182. Yuen, K. C. J. *et al.* AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE. *Endocr Pract* **25**, 1191-1232 (2019).

183. Hartman, M. L. *et al.* Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? *J Clin Endocrinol Metab* **87**, 477-485 (2002).

184. Einaudi, S. *et al.* Hypothalamo-hypophysial dysfunction after traumatic brain injury in children and adolescents: a preliminary retrospective and prospective study. *J Pediatr Endocrinol Metab* **19**, 691-703 (2006).

185. Gleeson, H. K., Gattamaneni, H. R., Smethurst, L., Brennan, B. M. & Shalet, S. M. Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy. *J Clin Endocrinol Metab* **89**, 662-666 (2004).

186. Alatzoglou, K. S., Webb, E. A., Le Tissier, P. & Dattani, M. T. Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. *Endocr Rev* **35**, 376-432 (2014).

187. Colao, A. *et al.* A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. *J Clin Endocrinol Metab* **94**, 4414-4422, doi:10.1210/jc.2009-1134 (2009).

188. Garcia, J. M. *et al.* Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. *Endocr Connect* **10**, 76-83 (2021).

189. Kuzma, M. *et al.* Effect of growth hormone on bone status in growth hormone-deficient adults. *Bratisl Lek Listy* **114**, 689-695 (2013).

190. Davidson, P., Milne, R., Chase, D. & Cooper, C. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. *Clin Endocrinol (Oxf)* **60**, 92-98 (2004).

191. Carroll, P. V. *et al.* Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. *J Clin Endocrinol Metab* **89**, 3890-3895 (2004).

192. Yang, H. *et al.* Body composition and metabolic health of young male adults with childhood-onset multiple pituitary hormone deficiency after cessation of growth hormone treatment. *J Pediatr Endocrinol Metab* **31**, 533-537 (2018).

193. Courtillot, C. *et al.* Monocentric study of 112 consecutive patients with childhood onset GH deficiency around and after transition. *Eur J Endocrinol* **169**, 587-596 (2013).

194. Elbornsson, M. *et al.* Fifteen years of GH replacement improves body composition and cardiovascular risk factors. *Eur J Endocrinol* **168**, 745-753 (2013).

195. Hwu, C. M. *et al.* Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. *J Clin Endocrinol Metab* **82**, 3285-3292 (1997).

196. Hammarstrand, C. *et al.* Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement. *Eur J Endocrinol* **179**, 229-237 (2018).

197. Attanasio, A. F. *et al.* Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. *J Clin Endocrinol Metab* **95**, 74-81 (2010).

198. Luger, A. *et al.* Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study. *Diabetes Care* **35**, 57-62 (2012).

199. Attanasio, A. F. *et al.* Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. *J Clin Endocrinol Metab* **96**, 2255-2261 (2011).

200. Lanes, R. *et al.* Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. *J Clin Endocrinol Metab* **86**, 1061-1065 (2001).

201. Setola, E. *et al.* Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. *Metabolism* **57**, 1685-1690 (2008).

202. Tidblad, A., Bottai, M., Kieler, H., Albertsson-Wikland, K. & Sävendahl, L. Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity. *JAMA Pediatr* **175**, e205199 (2021).

203. Grimberg, A. Cardiovascular Disease in Former Pediatric Recipients of Growth Hormone: Another Look at Growth Hormone Safety. *JAMA Pediatr* **175**, e205232 (2021).

204. Aguiar-Oliveira, M. H. & Salvatori, R. Disruption of the GHRH receptor and its impact on children and adults: The Itabaianinha syndrome. *Rev Endocr Metab Disord* **22**, 81-89 (2020).

Competing interests:

R.S. has served on NovoNordisk and Ipsen advisory boards.
M.D. has served on Novo Nordisk, Pfizer and Ipsen advisory boards and has received consulting/lecture fees from Sandoz, Pfizer and Novo Nordisk.
M.M. has served on Ascendis, Biomarin, Merck, Novo Nordisk, Pfizer, and Merk advisory Board and received lecture fees at several meetings.
S.L. received lecture fees and served on advisory board for Merck Serono, Ipsen, and Sandoz.

Highlighted References

Secco, A. *et al.* The glucagon test in the diagnosis of growth hormone deficiency in children with short stature younger than 6 years. *J Clin Endocrinol Metab* **94**, 4251-4257 (2009).
11. This study shows that children younger than 6 years with GHD can have normal GH peaks after glucagon administration.

Binder, G. *et al.* Diagnosis of severe growth hormone deficiency in the newborn. *Clin Endocrinol (Oxf)* (2020).
15. A comprehensive and updated review of the pituitary stalk interruption syndrome for further reading.

Hess, O. *et al.* Variable phenotypes in familial isolated growth hormone deficiency caused by a G6664A mutation in the GH-1 gene. *J Clin Endocrinol Metab* **92**, 4387-4393 (2007).
57. A thought-provoking paper detailing the variable penetrance associated with a single mutation in GH1; some patients within the same family with this mutation manifested no phenotype.

Gregory, L. C. & Dattani, M. T. The Molecular Basis of Congenital Hypopituitarism and Related Disorders. *J Clin Endocrinol Metab* **105** (2020).
109. A recent and up to date review of the molecular causes of congenital hypopituitarism.

Godano, E. *et al.* Role of MRI T2-DRIVE in the assessment of pituitary stalk abnormalities without gadolinium in pituitary diseases. *Eur J Endocrinol* **178**, 613-622 (2018).
130. This paper provides important evidence forMRI usage without contrast in the majority of children with GHD.

Sävendahl, L. *et al.* Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. *J Clin Endocrinol Metab* **97**, E213-217 (2012).
173. This paper presents a composite analysis of the data collected during the SAGhE study of the long-term safety of GH treatment.

Yuen, K. C. J. *et al.* AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE. *Endocr Pract* **25**, 1191-1232 (2019).
182.The most recently updated guidelines for pediatric GHD transitioning to adult care provides a practical tool for more in-depth detail.
Aguiar-Oliveira, M. H. & Salvatori, R. Disruption of the GHRH receptor and its impact on children and adults: The Itabaianinha syndrome. *Rev Endocr Metab Disord* (2020).

204. The GHRH signal disruption syndrome in a 26-year followed cohort has been a valuable model to study the GH roles in body size and function.

Supplementary information

Supplementary information is available for this paper at https://doi.org/10.1038/s415XX-XXX-XXXX-X

Display Items

Table 1:MRI findings in hypopituitarism

Aetiology	Pituitary phenotype	MRI findings
Idiopathic GHD	Normal pituitary	No evidence of morphologic, volumetric and signal abnormalities
	Isolated pituitary hypoplasia	Small anterior pituitary (height < 3 mm) or severe hypoplasia (height <2 SDS) housed within a small or normal pituitary fossa.
	Empty sella or intra-seller arachnoidocele	Deep and small or enlarged pituitary fossa, mainly filled with CSF. The anterior pituitary appears as a thin layer along its floor. Laminar appearance of the posterior lobe flattened against the dorsum sellae. Stretched pituitary stalk, posteriorly dislocated.
	Pituitary gland agenesis or atrophy	Absence of a clearly identifiable pituitary gland. Small and flat sella.
	Ectopic posterior pituitary	Variable degree of anterior pituitary hypoplasia, absence or marked thinning or hypoplasia of the pituitary stalk and ectopic posterior lobe from median eminence to the distal stalk. Sometimes double or partial ectopic posterior pituitary or ectopic posterior pituitary flattened within a thin pituitary stalk.
	Central nervous system abnormalities	Chiari I malformation; sporadic noncomplex abnormalities.
Genetic GHD	Normal pituitary	No evidence of morphologic, volumetric and signal abnormalities.
	Isolated pituitary hypoplasia	Small anterior pituitary (height < 3 mm)or severe hypoplasia (height <-2SDS) housed within a small or normal pituitary fossa.
	Empty sella/Intra-seller arachnoidocele	Deep and small or enlarged pituitary fossa, mainly filled with CSF. The anterior pituitary appears as a thin layer along its floor. Laminar appearance of the posterior lobe flattened against the dorsum sellae. Stretched pituitary stalk, posteriorly dislocated.
	Pituitarygland agenesis/atrophy	Absence of a clearly identifiable pituitary gland. Small and flat sella.
	Anterior pituitary hyperplasia	Anterior pituitary enlargement mimicking a sellar mass lesion (associated with *LHX3*, *PROP1* or *SOX2* mutations). Tendency to spontaneous regression and evolution into

		pituitary hypoplasia or intermittent hyperplasia in *PROP1* associated GHD; cystic pituitary in *LHX3*associated GHD
	Ectopic posterior pituitary	Variable degree of anterior pituitary hypoplasia, absence or marked thinning or hypoplasia of the pituitary stalk and ectopic posterior lobe from median eminenceto the distal stalk.Sometimes double or partial ectopic posterior pituitary or ectopic posterior pituitaryflattened within a thin pituitary stalk.
	Central nervoussystem abnormalities	Persistent craniopharyngeal canal,Chiari type I, Chiari type II, corpus callosum dysgenesis, septum pellucidum agenesis,vermis cerebellar dysplasia,periventricular heterotopia, basilar impression, sellar or suprasellar arachnoid cyst,tentorial anomaly, cortical dysplasia, schizencephaly, frontotemporal lobe hypoplasia, holoprosencephaly, hippocampalabnormalities, absence of internal carotidartery, absence or hypoplasia of olfactory bulbs and olfactory tracts,syringomyelia, hypothalamic hamartoma, variable spectrum of abnormalities in Septo optic dysplasia (optic nerve hypoplasia or aplasia, thin optic tracts,coloboma, anophthalmia, microphthalmia, midbrain-hindbrain abnormalities) and other forebrain, midbrain and hindbrain anomalies

MRI, magnetic resonance imaging; GHD,growth hormone deficiency; SDS,standard deviation score; CSF, cerebrospinal fluid

Figures

Figure 1: Normal MRI study in a healthy 9-year-old boy.MRI protocol consisted of 2–3 mm thick, high-resolution spin-echo T1- and turbo–fast spin-echo T2-weighted images on sagittal and coronal planes. T2-DRIVE sequence is acquired on the sagittal plane with a slice thickness of 0.6 mm (25 slices) and a scan time of 2 min and 32 s, using a 3D technique with isotropic voxels (0.6 × 0.6 × 0.6 mm) that allows multiplanar reformatting with no geometric distortion. ; *B.* **A** |A sagittal T1-weighted image of hyperintense posterior pituitary lobe (PPL), anterior pituitary lobe (APL), pituitary stalk (PS), median eminence (ME), optic chiasm (OC), and tuber cinereum (TC) (white arrows). **B** |A gadolinium-enhanced sagittal T1-weighted image ofenhancement of PP, PS and TC after gadolinium(white arrows). **C** |A gadolinium-enhanced coronal T1-weighted image of internal carotid arteries (ICA) and gadolinium-enhanced cavernous sinuses (CS) (white arrows); PG cannot be confidently separated into the APL and PPL. **D** |A sagittal T2-DRIVE image, in which PS (black arrowhead) is optimally depicted with sharp delineation of the infundibular recess of the third ventricle (IR); additional midline

structure including the lamina rostralis (LR), anterior commissure (AC), lamina terminalis (LT), Liliequist membrane (LM).

Figure 2: Pathological MRI in children with hypopituitarism. Sagittal T1-weighted images showing the classic triad of ectopic posterior pituitary (arrow) associated with a variable location of the posterior pituitary. Median eminence (A,B), mid pituitary stalk (C,D) with a double posterior pituitary (E), and distal stalk (E,F). Pituitary stalk is absent (A,B,C), or hypoplastic or thin (D,E,F). Anterior pituitary is of variable size from severe hypoplasia (A,B) to mild hypoplasia (C-F). The current practice points for an MRI work-up in hypopituitarism are as follows: MRI without contrast-medium using T2-DRIVE sequences of the hypothalamic–pituitary region and the entire brain (forebrain, midbrain, and hindbrain)is highly recommended in neonates, infants and children with signs and symptoms suggestive of hypopituitarism (such as hypoglycaemia, cholestatic jaundice and other signs). First-line MRI examination without GH testing could be performed.MRI is also highly recommended in: children and adolescents with severe short stature and GH testing compatible with the diagnosis of GHD; in children and adolescents with MPHD; and in children with IGHD and severe short stature (evolving pituitary defects are possible over time). MRI could be of low value in children with IGHD and less severe GHD defined based on the local GH cut-off (> 3 or >5 or >7 or 10> ng/ml). A personalized decision is advisable.

Figure 3 - MRI findings in congenital hypopituitarism based on the genotype.

A practical algorithm that shows MRI assessment of patients with suspected hypopituitarism. Correlations between MRI phenotype and genotype, based on endocrine status in IGHD, syndromic, or non-syndromic MPHD, provide a straightforward approach to breaking down the differential diagnosis lists into more manageable categories

IGHD, isolated growth hormone deficiency; MPHD, multiple pituitary hormone deficiency; AP, anterior pituitary; PSIS, pituitary stalk interrupted syndrome; EPP, ectopic posterior pituitary; HPE, Holoprosencephaly, and HPE-related genes; ^IGHD/MPHD; [a]Variable MRI pituitary abnormalities including normal pituitary stalk, ectopic posterior pituitary, and central nervous system abnormalities (CNS); [b]Anterior pituitary hyperplasia/sometimes intermittent/hypoplasia.

Box 1: Aetiologies of GHD

[bH1] IGHD — genetic causes

[b1]*GH1* mutations (GHD type IA or IB)

[b1] *GH1* mutations (GHD type II with evolving pituitary deficiencies)

[b1] *GH1* Kowarski Syndrome (bioinactive GH)

[b1] GHD type III(supplementary table 1)

[b1] *GHRHR* mutations (GHD type IV)

[b1] *GHS* mutation or variant

[b1] GH in syndromes (supplemental tables 1 and 2)

[b1] RNPC3 mutations

[bH1] MPHD — genetic causes

[b1] Genes implicated in early development of hypothalamic–pituitary region; for example, *HESX1*, *LHX3* or *LHX4*

[b1] Genes implicated in early development of brain and hypothalamic–pituitary region

[b2] Holoprosencephaly – several genes; for example, *SHH*, *GLI2* or *FGF8*

[b2] Septo-optic dysplasia and its spectrum involving eyes; for example, *HESX1* or *OTX2*

[b2] Midline defects (such as cleft-palate, persistence of craniopharyngeal canal or dental agenesis); for example, EDA or WNT10A

[b2] Extra brain malformations; for example, ARNT2, CHD7 or IGSF1

[b2] Overlapping Kallmann syndrome; for example, *FGF8*, FGFR1, PROKR2, PROK2, CDH7 or WDR11

[b2] Genes associated with other early development conditions

[b1] Genes implicated in cellular differentiation

[b1] Tumour-inducing genes (for example, *SOX2* or*BRAF*)

[bH1] MPHD — congenital defects

[b1] Midline brain and pituitary developmental defects

[b1] Pituitary aplasia; ectopic posterior pituitary, anterior pituitary hypoplasia and pituitary stalk abnormalities (agenesis or hypoplasia); empty sella

[b1] Congenital CNS mass (hamartoblastoma or hamartoma), cyst, encephalocele

[bH1] IGHD or MPHD—acquired

[b1] CNS tumours (craniopharyngioma, germinoma, ependymoma, pituitary adenoma, meningioma, medulloblastoma, glioma, metastatic tumours (rare), Rathke's cleft cyst, arachnoid cyst

[b1] Radiotherapy (cranial irradiation for CNS tumours, other malignancies orBMT)

[b1] TBI (accidental, after neurosurgery or subarachnoid hemorrhage)

[b1] Infections (meningitis, encephalitis, tuberculosis or hypophysitis)

[b1] Autoimmune (hypophysitis, APS or anti-PIT1antibodies)

[b1] Infiltration (LCH, haemochromatosis, chronic blood transfusions or sarcoidosis)

[bH1] IGHD or MPHD — idiopathic permanent

[bH1] IGHD or MPHD — idiopathic transitory

GH, growth hormone; GHD, growth hormone deficiency; IGHD, isolated growth hormone deficiency; MPHD, multiple pituitary hormone deficiency; CNS, central nervous system; BMT, bone marrow transplantation; TBI, traumatic brain injury; APS, autoimmune polyglandular syndrome; LCH, Langherans cell histiocytosis

Box 2:Criteria to initiate immediate investigation for GHD
[bH1] Height
[b1] 3 SD below the mean
[b1] 1.5 SD below the midparental height
[b1] 2 SD below the mean + height velocity per year 1 SD below the mean for CA
[bH1] Height velocity
[b1] 2 SD below the mean over 1 year
[b1] 1.5 SD below the mean sustained over 2 years
[bH1] Other signs
[b1] Intracranial Lesion
[b1] MPHD
[b1] Neonatal GHD

CA, chronological age; GHD, growth hormone deficiency; MPHD, multiple pituitary hormone deficiency;SD, standard deviation.

Glossary

Holoprosencephaly: this syndrome is caused by a failure of separation of the cerebral hemispheres and ventricles and is associated with a wide range of midline facial defects, ranging from cyclopia to midfacial hypoplasia, cleft lip/ palate, and a single incisor.

T2-DRIVE: A T2-weighted driven equilibrium (DRIVE) imaging obtained via turbo/fast spin-echo sequences at a sub-millimetric thickness that provide excellent contrast between the cerebrospinal fluid and the adjacent parenchymal structures.

Ectopic posterior pituitary: A disruption of normal embryogenesis of the posterior pituitary resulting in an incomplete downward extension of the diencephalon (infundibulum).

Slipped capital femoral epiphysis: A disorder of adolescents in which the growth plate is damaged and the femoral head moves (“slips”) with respect to the rest of the femur. The head of the femur stays in the cup of the hip joint while the rest of the femur is shifted (similar to an ice cream scoop falling off of the ice cream cone).

In children, growth hormone (GH) deficiency (GHD) results in growth failure and has multiple different causes. This Review discusses diagnosis of GHD in children and highlights advances in management, including transitional care.